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57 ABSTRACT 
A process is described for the preparation of the core 
azobicyclof.3.1tridecaenediyne moiety of the antitu 
mor antibiotic dynemicin. The synthesis allows efficient 
production of the enediyne as a stable, compound in 
good yield from the adamantyl N-protected azabicy 
clof.3.1tridecadiyne. The adamanty protecting group 
is employed in the starting material, N-adamantyl dihy 
droquinoline or N-adamantyl 6-methoxy quinoline. 
Also disclosed are process for the synthesis of 3 
hydroxy-6-methoxyquinoline and several N-substituted 
derivatives of azobicyclo7.3.1tridecaenediyne. Solid 
tumor and leukemia assays were performed on the ana 
logs of dynemicin. The results suggest a method that 
these compounds will useful in treating certain types of 
leukemias and solid tumors. The disclosed synthesis 
provides a route to new dynemicin intermediates and 
analogs which will allow development of second and 
third generation dynemicins. 
1 Claim, 10 Drawing Sheets 
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SYNTHESIS OF TETRAHYDROQUINOLINE 
ENEDIYNE CORE ANALOGS OF DYNEMCIN 
The United States Government owns rights in the 
present invention pursuant to grant No. CHE 9025126 
from the National Science Foundation. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The invention is concerned with novel antitumor/an 
tibiotic compounds related to dynemicin which contain 
a core tetrahydroquinoline enediyne structure and to 
novel methods of synthesis of analogs and derivatives of 
these compounds. Also disclosed are pharmaceutical 
compositions employing various of the new compounds 
as antitumor agents. 
2. Description of Related Art 
Enediyne anticancer antibiotics are a recently discov 
ered class of compounds with potent biological activi 
ties. This class of compounds includes neocarzinostatin, 
esperamicin, and, more recently, dynemicin, as well as 
calicheamicin. The enediyne moiety is a bicyclo 
7.3.Ododecaenediyne chromophoric system. The un 
usual molecular architecture contributes to the excep 
tional biological activity and mode of action of ene 
diyne compounds which are believed to exert their 
effect as DNA cleaving compounds operating through 
a free radical mechanism. Such cleaving properties are 
derived from the ability to generate Sp?carbon centered 
radicals after activation (Nicolaou and Dai, 1991). 
The different groups of enediyne anticancer antibiot 
ics exhibit similar biological activities, but may differ 
significantly in target and toxicity. Neocarzinostatin 
was originally isolated from a culture of Streptomyces 
carzinostaticus. Compounds of this class exhibit potent 
antitumor antibacterial action. The calicheamicins are 
isolated from Micromonospora echinospora ssp. calichen 
sis. This subclass of compounds is highly active against 
both gram positive and gram negative bacteria and also 
exhibits unusual high activity against murine tumors 
such as P338, L1210 leukemias and solid neoplasms 
such as COLN26 and B-16 melanoma. Esperamicins 
have been isolated from cultures of Actinomadura ver 
rucosospora and are similar in their activities to the cali 
cheamicins. Structurally, the esperamicins contain a 
bicyclo 7.3.1tridecaenediyne ring system, an allylic 
trisulfide (or tetrasulfide), a 1,5-diyn-3-ene moiety as 
pan of the ring system, and an afé-unsaturated ketone in 
which the double bond is at the bridgehead of the bicy 
clic core. These compounds are extremely potent anti 
cancer agents and exhibit activity against several mu 
rine tumor models, including P388, B16, and 5076. 
A more recently discovered class of enediynes are the 
dynemicins. These violet-colored antibiotics were iso 
lated from fermentation cultures of Micromonospora 
chersina. Studies in vitro and in vivo have demonstrated 
that these compounds are active against a variety of 
cancer cell lines. They have been shown to significantly 
prolong the life of mice inoculated with P388 leukemia 
and B16 melanoma cells. The dynemicin family of com 
pounds combines low toxicity with good in vivo anti 
bacterial activity. Deoxydynemicin, like the parent 
dynemicin, is also biologically active. Structurally, the 
dynemicins include a ten-membered ring with a 1,5- 
diyn-3-ene bridge; however, they differ structurally 














1,5-diyn-3-ene antibiotics have generated consider 
able interest and challenge to synthesize new active 
compounds which have the unique 1,5-diyn-3-ene core. 
Several reports have indicated successful synthesis of 
the core diyne structure. Calicheamicinone has been 
totally synthesized (Hazeltine et al., 1991). The synthe 
sis employed application of the Becker Alder reaction 
to obtain an appropriately substituted brominated benz 
aldehyde, an in situ protection, and an intramolecular 
Emmons-like closure in an annulation procedure. The 
final product, calicheamicinone, represents the agly 
cone moiety of calicheamicin y-1 and esperamicin a1. 
The aglycon portion of calicheamicin y-1 has also 
been synthesized (Smith et al., 1992). In that synthetic 
approach, the molecule was synthesized via an intramo 
lecular alkenyl nitrile oxide dipolar cycloaddition reac 
tion leading directly to incorporation of the full func 
tionality of the aglycon. 
Other approaches to the synthesis of the ene-diynes 
ofesperamicin/calicheamicin have provided a synthesis 
of 2-ketobicyclo (7.3.1enediyne and 13-ketocyclo 
7.3.1 enediyne through the use of m2 dicobalt hexacar 
bonyl, alkyne complexes. This synthesis is based on 
complexing the 10, 11-acetylenic bond with a dicobalt 
hexacarbonyl compound (Magnus and Fortt, 1991). 
Several approaches to a simple and efficient route to 
a dynemicin A model system have been reported. In 
contrast to the above strategies, a transannular Diels 
Alder route has resulted in polycyclizations to dynemi 
cin-type molecules (Porco et al., 1990). Other synthetic 
routes have been reported (Nicolaou et al., 1990). Two 
novel dynemicin. A compounds containing the epoxide 
and the ene-diyne functionalities of the parent com 
pound were synthesized with either hydrogen or hy 
droxyl at one of the bridgehead positions. Other model 
dynemicin A compounds have been prepared starting 
from 7,8,9,10-tetrahydrophenanthridine. The com 
pounds produced in these syntheses were N-protected 
derivatives (Nicolaou et al., 1991). The N-protected 
model systems failed to exhibit any activity when incu 
bated with dbx 174 DNA. However, some activity was 
observed when the N protecting group was removed. 
The free amine was unstable although activity in crude 
mixtures caused double-stranded DNA cleavage similar 
to that observed for the parent compound dynemicin A. 
An alternate synthesis of the core tetrahydroquino 
line enediyne structure using £2 hexacarbonyl dicobalt 
acetylene complexes has been reported (Magnus & 
Fortt, 1991). An important step in this synthesis was 
complexation of one of the intermediates as a hexacar 
bonyl dicobalt complex. By employing a cation solvat 
ing solvent for the formation of the azabicyclo 
7.3.0diynene, a stable azabicyclo 7.3.1trideca 
enediyne core structure was obtained. In another ap 
proach, a transannular Dieis-Alder polycyclization and 
an allylic diazine rearrangement have provided an inter 
mediate that was transformed to the ene-diyne bridged 
tricyclic core of diynemicin A (Wood et al., 1992). 
While a number of approaches to the synthesis of 
enediynes and particularly aimed at the total synthesis 
of diynemicin A have been explored, there exists a need 
for analogs containing the core enediyne bridged tricy 
clic diynemicin A core. An improved synthesis would 
provide more efficient entry to novel compounds with 
expanded antibiotic and antitumor activities. 
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SUMMARY OF THE INVENTION 
The present invention seeks to overcome these prob 
lems and other drawbacks inherent in the prior art by 
providing an improved synthesis of the azabicy 
clo7.3.1tridecaenediyne core structure of the antitu 
mor antibiotic dynemicin. The invention also relates to 
analogs and derivatives of the enediyne which show in 
vivo antitumor activity. Also disclosed is an efficient 
synthesis of 3-hydroxy-6-methylquinoline which may 
be used as a starting compound for the synthesis of 
dynemicin core analogs and derivatives. 
In general, the method relates to a process for prepar 
ing azobicyclo7.3.1tridecaenediyne or more specifi 
cally in chemical terms N-(methoxy)carbonyl-15-keto 
13-methoxy-10-aza-14a, 10a-benzobicyclo/.3.1tridec 
3,7-diyn-5-ene. The process involves the steps of first 
reacting an O-protected 3-hydroxyquinoline with a 
magnesioacetylide prepared from the tetrahydropyra 
nyl ether of Z-hept-4-ene-2,6-diyn-1-ol. Protection of 
the 3-hydroxyl group is preferably with a silyl group 
such as trimethylsilyloxyl, tri-isopropylsilyloxyl or, 
preferably, 3-t-butyldimethylsilyloxyl. A chloroformate 
is added to the reaction mixture to form an N-protected 
dihydroquinoline. 
N-substitution is readily effected by treating one of 
the hydroxy quinoline starting materials with a chloro 
formate to obtain an alkyl such as methyl, ethyl, etc., 
benzyl, phenyl, cholesterol, menthyl or, preferably, 
adamanty carbamate. The inventors have discovered 
that the N-adamantyl protecting group is quite unex 
pectedly preferred over other protecting groups be 
cause it may be readily hydrolyzed to form the ben 
zobicyclo/.3.1tridec-3,7-diyn-5-ene dynemicin core, 
Other protecting groups such as N-methoxycarbonyl or 
chloroethyl groups are not satisfactory because basic or 
nucleophilic conditions are required for their removal. 
These reaction conditions result in low yields because 
of extensive destruction of the enediyne core. Under 
basic conditions, an aromatized adduct is formed. In 
contrast, the adamantyl carbamate group is readily re 
moved with trifluoroacetic acid and dichloromethane at 
room temperature to give high yields of the deprotected 
amine, typically in yields exceeding 80%. 
The silyloxy protecting group of the N-adamantyl 
protected 6-alkoxysilyl ether-protected magnesioacety 
lide is readily removed to afford the primary alcohol by 
using such reagents as pyridinium tosylate/ethanol (the 
Grieco procedure). 
The acetylide is then treated with Co2(CO)8 to form 
a hexacobalt m2-Co2(CO)6 complex. The major product 
is a cobalt complex formed at the 3-4 acetylenic position 
but some complex at the acetylenic 7-8 position is also 
formed. The undesired regioisomer at the 7-8 position 
may be recycled by oxidation to the diacetylenic com 
pound which is then treated with dicobaltoctacarbonyl. 
While ceric ammonium nitrate is the preferred oxidizing 
agent, other similar oxidants may be used including, for 
example, any transition metal oxidant, N-oxides of 
amines, Fe(NO3)3 or FeCl3. 
The advantage of the cobalt complex is that it is 
readily cyclized in cation-solvating solvents. Other 
solvents such as CH2Cl2 (trifluoromethanesulfonic an 
hydride-2,6-di-tert-butyl-4-methylpyridine) at low tem 
peratures fail to promote cyclization. This unusual sol 
vent effect on m2-hexacarbonyldicobalt propargylic 














The last step in the process to achieve the benzobicy 
clo7.3.1tridec-3,7-diyn-5-ene molecule is to remove 
the adamantyl N-protecting group. As previously dis 
cussed, the adamantyl group is readily removed. The 
free amine is stable and obtained in an overall yield of at 
least 80%. Surprisingly, removal of the N-protecting 
group provides a stable, free amine. Other protecting 
groups such as ethyl chloroformate, cannot be removed 
without substantially destroying the bicyclo ring sys 
tem. In retrospect, the inventors believe that while the 
chloroformate group is generally removable under 
acidic conditions, it is such conditions that promote 
instability in the tridecaenediyne molecule thereby lead 
ing to destruction of the bicyclo ring. On the other 
hand, groups such as adamantyl which are readily re 
moved under electrophilic conditions leave the core 
structure intact. It has been found that the adamanty) 
group is superior to other groups tested; however, it is 
possible that other alicyclic bicyclo or fatty acid ana 
logs might also provide good results. 
In a similar manner, 15-keto- 10-aza- 14a, 10a-ben 
zobicyclo7.3.1tridec-3,7-diyn-5-ene may be readily 
synthesized by reacting a 3-hydroxy protected quino 
line with hydroxyl protected magnesioacetylide and 
adamantyl chlorocarbonate and following the steps 
previously discussed. 
In an alternate synthesis of the 13-methoxy ben 
zobicyclo7.3.1.tridec-3,7-diyn-5-enes, it is not neces 
Sary to use a 6-methoxy 3-hydroxyquinoline as a start 
ing material. The 13methoxy compounds may be pre 
pared by forming an epoxide across the 3,4-position 
before complexation to form the cobalt complex. The 
epoxide may be formed by peroxidation using any per 
acid Such as m-chloroperbenzoic acid; however, this is 
preferably performed in the presence of bicarbonate. 
Further reaction with an aryl selenide such as phenyl 
selenide and a trialklychlorosilane or trifluorosulfonate 
followed by elimination across the 3,4-position results in 
an O-alkyl substitution at the 3-position which corre 
sponds to the 13-position in the final product. 
Other aspects of the invention include derivatives and 
analogs of the tetrahydroquinoline diynene core ana 
logs of dynemicin. N-substituted derivatives of the C-13 
O-methoxy enediyne, for example, are readily prepared 
from appropriately substituted chloroformates reacted 
with 6-methoxy O-protected 3-hydroxyquinoline and 
the appropriate magnesioacetylide as previously de 
scribed. The N-substituted compounds include a wide 
range of alkyl, aryl, benzyl, phenyl, heteroalkyl and 
aromatic substituents. Carbamate formation is well 
studied and extensively used. References are available 
to practitioners which contain extensive lists of N-sub 
stituents with commonly used procedures for synthesis 
(Green, 1989). 
Bridgehead analogs and derivatives of the diynene 
core are a particularly important group of compounds 
that may be readily synthesized. The inventors have 
discovered that the tetrahydroquinoline diynene com 
pounds readily enolize at the bridgehead position, 
thereby providing a route to substitution at the bridge 
head position. Substitution is readily accomplished by 
treating the diynene in the presence of a base with any 
of a number of electrophiles; for example, selenides, 
sulfonates, phosphonates, a-halo ethers and the like. 
Alternatively, electrophiles substituted at this position 
may be replaced with other groups; for example, by 




Other aspects of the invention include the use of the 
disclosed dynemicin derivatives and analogs as pharma 
ceutical agents. The parent compound, dynemicin, is a 
natural product known for its extraordinary potent 
antimicrobial and antitumor activities with relatively 5 
little in vivo toxicity. Acetate derivatives of dynemicin 
have shown even more activity than the parent com 
pound (Konishi et al., 1989). Now, for the first time, the 
inventors have described a process for making a core 
analog of dynemicin. This provides a route to the prepa 
ration of several compounds that show activity against 
solid tumors in vivo. 
The active compounds may be administered paren 
tally or intraperitoneally. Solutions of the active com 
pounds as the free base or pharmacologically accept 
able salts can be prepared in water suitably mixed with 
a surfactant such as hydroxypropyl cellulose. Disper 
sions can also be prepared in glycerol, liquid polyethyl 
ene glycol and mixtures thereof, and in oils. Under 
ordinary conditions of storage and use, these prepara- 20 
tions contain a preservative to prevent the growth of 
microorganisms. 
The pharmaceutical forms suitable for injectable use 
include sterile aqueous solutions or dispersions and 
sterile powders for the extemporaneous preparation of 25 
sterile injectable solutions or dispersions. In all cases, 
the form must be sterile and must be fluid to the extent 
that easy syringability exists. It must be stable under the 
conditions of manufacture and storage and must be 
conserved against the contaminating action of microor 
ganisms, such as bacteria and fungi. The carrier can be 
a solvent or dispersion medium containing, for example, 
water, ethanol, polyol (for example, glycerol, propy 
lene glycol, and liquid polyethylene glycol, and the 
like), suitable mixtures thereof, and vegetable oils. The 
proper fluidity can be maintained, for example, by the 
use of a coating such as lecithin, by the maintenance of 
the required particle size in the case of dispersion, and 
by the use of surfactants. The prevention of the action 
of microorganisms can be brought about by various 40 
antibacterial and antifungal agents, for example, parab 
ens, chlorobutanol, phenol, sorbic acid, thimerosal, and 
the like. In many cases, it would be preferable to use 
isotonic agents, for example, sugars or sodium chloride. 
Prolonged absorption of the, injectable compositions 45 
can be brought about by the use in the compositions of 
agents delaying absorption, for example, aluminum 
monostearate and gelatin. 
Sterile injectable solutions are prepared by incorpo 
rating the active compounds in the required amount in 
the appropriate solvent with various of the other ingre 
dients enumerated above, as required, followed by ster 
ilization, for example, by filtration sterilization. Gener 
ally, dispersions are prepared by incorporating the vari 
ous sterilized active ingredients into a sterile vehicle 
which contains the basic dispersion medium and re 
quired other ingredients from those enumerated above. 
In the case of sterile powders for the preparation of 
sterile injectable solutions, the preferred methods of 
preparation are vacuum drying and freeze drying tech- 60 
niques which yield a powder of the active ingredient 
plus any additional desired ingredient from a previously 
sterile filtered solution thereof. 
As used herein, "pharmaceutically acceptable car 
rier' includes any and all solvents, dispersion media, 65 
coatings, antibacterial and antifungal agents, isotonic 
and absorption delaying agents, and the like. The use of 








rations is well known in the art. Except insofar as any 
conventional media or agent is incompatible with the 
active ingredient, its use in the therapeutic compositions 
is contemplated. Supplementary active ingredients can 
also be incorporated into the compositions. Addition 
ally, "pharmaceutically acceptable' refers to molecular 
entities and compositions that do not produce an aller 
gic or similar untoward reaction when administered to 
a mammal. 
It is contemplated that many of the derivatives and 
analogs of the dynemicin core compounds can be for 
mulated into a composition in a neutral or salt form. 
Pharmaceutically acceptable salts include the acid addi 
tion salts (formed with the free amino group of the 
molecule) which are formed with inorganic acids such 
as, for example, hydrochloric or phosphoric acids, or 
organic acids such as acetic, oxalic, tartaric, mandelic, 
and the like. 
Upon formulation, solutions will be administered in a 
manner compatible with the dosage formulation and in 
such an amount as is therapeutically effective. The for 
mulations are easily administered in a variety of dosage 
forms, such as injectable solutions, drug release cap 
sules, and the like. For parenteral administration in an 
aqueous solution, for example, the solution should be 
suitably buffered if necessary and the liquid diluent first 
rendered isotonic with sufficient saline or glucose. 
These particular aqueous solutions are especially suit 
able for intravenous, intramuscular, subcutaneous, and 
intraperitoneal administration. In this connection, ster 
ile aqueous media which can be employed will be 
known to those of skill in the art in light of the present 
disclosure. For example, a dosage could be dissolved in 
one mL of isotonic NaCl solution and either added to 
1,000 mL of hypodermic fluid or injected into the pro 
posed site of infusion (see, for example, Remington's 
Pharmaceutical Sciences, 15th Edition, pp. 1035-1038, 
and pp. 1570-1580). Some variation in dosage will nec 
essarily occur, depending on the condition of the sub 
ject being treated. The person responsible for adminis 
tration will in any event determine the appropriate dose 
for the individual subject. 
The present invention has provided new approaches 
and routes to the class of natural products based upon 
the Z-enediyne functionality. For the first time, the 
stable free amine of the dynemicin core molecule has 
been synthesized. The method provides a convenient 
route to propargylic cation-type intermediates by mak 
ing use of the m2 dicobalt hexacarbonyl alkyne com 
plexes which may be trapped by a wide variety of car 
bon nucleophiles. The methods disclosed herein are 
applicable to the synthesis of the core structures of 
neocarzinostatin as well as dynemicin. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the structure of dynemicin. 
FIG. 2 is a scheme showing the synthesis of the core 
tetrahydroquinoline diynene portion of esperamicin. 
FIG. 3 shows the conversion of azobicyclo7.3.- 
lenediyne to the ring-closed azabicyclo benzodiyne 
compound. 
FIG. 4 shows the naphthalene product resulting from 
treatment of azabicyclo 7.3.1)diynene with sodium 
thiophenolate at 0°C. in tetrahydrofuran. 
FIG. 5 illustrates the removal of the adamantyl N 
protecting group from the azabenzobicyclo[7.3.1 tri 
dec-3,7-diyn-5-ene at room temperature with trifluoro 
5,442,065 
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acetic acid in dichloromethane to yield the deprotected 
amine. 
FIG. 6 is a scheme showing the synthesis of 3 
hydroxy-6-methoxyquinoline. 
FIG. 7 schematically illustrates the synthesis of the 
core tetrahydroquinoline diynene moiety of dynemicin. 
FIG. 8 indicates the numbering system for structures 
with the azabicyclof.3.1diynene system. 
FIG. 9 shows the structures of compounds 5582 and 
4429 which are dynemicin core analogs. 
FIG. 10 shows the enediyne dynemicin structure, 
indicating positions of substitution by reference to the 
experimental procedure provided in Example 4. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
Dynemicin 1 (R=H) is the latest antitumor antibiotic 
to be added to the growing list of diynene natural prod 
ucts. It exhibits extraordinary potent antimicrobial and 
antitumor activity, and moreover it shows relatively 
little in vivo toxicity. The derived triacetate 2 
(R=OAc) is even more hnpressive. 
The synthesis of the core tetrahydroquinoline diy 
nene structure 9 using m2-dicobalthexacarbonyl acety 
lene complexes is shown schematically in FIG. 2. The 
synthesis utilizes simple starting materials and porvides 
a route to a wide range of diynene derivatives. 
Treatment of the t-butyldimethylsilyl ether of 3 
hydroxyquinoline 3 with the magnesioacetylide 4 in the 
presence of a variety of chloroformates gave, in a com 
pletely regiospecific reaction, the dihydroquinoline 
5R=Me (86%), R=CH2CH2Cl (71%, R=adamantyl 
(63%). Selective deprotection of the THP ether to 
give 6R=Me (87%), R=CH2CH2Cl (64%), R=ada 
mantyl (74%) was accomplished using the Grieco pro 
cedure (pyridinium tosylate/EtOH) (Miyashita, et at., 
1977). 
Complexation of 6 with Co2(CO)8 gave 7 R=Me 
(47%) R=CH2CH2Cl (56%) R=adamantyl (60%) 
along with some complexation at the other acetylene 
(ca. 15%) and biscomplexation. The desired regioiso 
mer can be separated from the other regioisomer by 
chromatography. The undesired regioisomer can be 
oxidized with ceric ammonium nitrate (CAN) to give 6, 
which can be recycled. 
Treatment of 7 with trific anhydride/2,6-di-t-butyl 
4-methylpyridine (DBMP) in PriNO2 at -10° C. gave 
the cyclized product 8 (54%). Oxidative decomplexa 
tion of 8 using CAN/acetone/-10 C. gave 9 (42%). 
The overall yield of 9 from 7 for the different carba 
mates is as follows R=Me (23%, R=CH2CH2Cl 
(24%), R=adamantyl (60%)). 
The dynemicin core azobicyclo7.3.1diynene 9 
proved to be remarkably resistant to cycloaromatiza 
tion. It required heating in 1,4-cyclohexadiene at 124 
C. for hours to convert it into 10 (84%), giving an ap 
proximate AG30.9 kcal moll (FIG. 3). 
The adamantyl carbamate protecting group was 
chosen with the expectation that it should be readily 
removed under acidic conditions. Carbamates that re 
quire basic or nucleophilic conditions for their removal 
are precluded since, for example, treatment of 9 with 
sodium thiophenolate in tetrahydrofuran at 0° C. rap 
idly gave the: completely aromatized adduct 11 (FIG. 
4). The position of the thiophenyl group is uncertain, 
but the compound is definitely a naphthalene deriva 













gave compound 11a, as deduced from X-ray crystallog 
raphy. 
It was found that treatment of the adamantyl carba 
mate 9 (R=adamantyl) with trifluoroacetic acid in di 
chloromethane at room temperature gave the de 
protected amine 12 in 81% yield (FIG. 5). Starting with 
3-(tert-butyldimethylsilyloxy)-6-methoxyquinoline, the 
same sequence of transformations to make the methoxy 
analogue of 12 was carried out. 
3-Hydroxy-6-methoxyquinoline is not, a known con 
pound, and the common methods for synthesizing 
quinolines are not readily applicable to 3-hydroxy sub 
stituents. p-Anisidine hydrochloride was treated with 
sodium nitromalonaldehyde to give the enamine 13. 
Heating the enamine 13 in a mixture of acetic acid sulfo 
lane gave 3-nitro-6-methoxyquinoline 14 (30%). The 
yield of 14 could be improved to 48%, by heating p 
anisidine hydrochloride and the enamine 13 in acetic 
acid in the presence of a catalylic amount of 3,5dime 
thylthiophenol. Reduction of 14 using stannous chloride 
gave 3-amino-6methoxyquinoline 15 (86%). Standard 
diazotization conditions and hydrolysis gave the phenol 
16 (95%). Treatment of 16 with t-butyldimethylsilyl 
chloride/imidazole/in dimethylformamide gave 17 
(91%) (FIG. 6). 
FIG. 7 shows conversion of 17 to 25. The quinoline 
17 was coupled to 18 in the presence of adamantyl chlo 
roformate to give 19 (75%). Hydrolysis of the tetrahy 
dropyranyl ether 19 with pyridinium tosylate gave the 
alcohol. 20 (89%). Complexation of 20 with dicobaltoc 
tacarbonyl in tetrahydrofuran gave 21 (59%), 23 
(traces) and 22 (33%). The undesired regioisomer 22 
can be recycled by ceric ammonium nitrate oxidation to 
give 20 (76%). 
Treatment of the cobalt adduct 21 with triflic anhy 
dride/2-nitropropane/2,6-di-tert-butyl-4-methylpyri 
dine at -10° C. for 30 min. gave 21a. Direct oxidative 
work-up by ceric ammonium nitrate oxidation gave the 
cyclized enediyne 24 (53%, for the two steps.) The 
adamantyl carbamate was removed by treatment of 24 
with trifluoroacetic acid in dichloromethane to give the 
amine 25 (78%). 
EXAMPLE 1. 
The detailed experimental procedures for the synthe 
sis of the N-(methoxy)carbonyl)-15-keto-10-aza-14a, 
10a-benzobicyclo (7.3.1) tridec-3,7-diyn-5-ene and the 
13-methoxy analog are described below. The number 
ing system for the enediyne is shown in FIG. 8. General 
method for the synthesis of 5 (R-Me, R = CH2CH2Cl, 
and R=adamantyl). 
Ethylmagnesium bromide (23.0 ml 1 M, 0.023 mol) 
was added to a cooled solution of Z-hept-4-ene-2,6- 
diyn-1-ol tetrahydropyranyl either 3.63 g (0.019 mol) in 
30 ml of THF, stirred for 20 minutes followed by addi 
tion of 3-tert-butyldimethylsilyl (oxy) quinoline 4.46g 
(0.017 mol) in 20 ml of THF. The chloroformate (2.66 
ml, 0.034 mol) was then slowly added over a period of 
2 hrs and the mixture to stirred overnight. The reaction 
mixture was poured onto saturated aqueous NH4C1, the 
layers separated and the aqueous layer extracted with 
diethyl either (3 x 100 ml). The organic layers were 
dried (MgSO4) and concentrated in vacuo. The crude 
product was chromatographed over silica gel eluting 
with 5% ether/pentane to give the product 5 (5.92 g, 
68%). 
5 R=Me (86% yield). 
5,442,065 
Rf 0.22 (95:5-pentane: ether); H NMR (300 MHz, 
CDCl3) 87.56 (bs, 1H), 7.18-6.98 (m, 3H), 5.80-5.63 (m, 
4H), 4.77 (s, 1H), 4.37-4.21 (m, 4H), 3.82 (s, 3H), 
3.56-3.52 (m, 2H), 1.89-1.51 (m, 6H), 0.97 (s, 9H), 0.26 
(s, 6H); 13C NMR (75 MHz, CDCl3) 81539, 150.5, 
130.9, 127.7, 125.2, 125.0, 124.5, 123.9, 119.7, 118.9, 
116.2, 104.8, 96.6, 93.0, 92.5, 82.6, 80.5, 65.7, 61.8, 54.5, 
53.3, 49.2, 30.2, 25.4, 19.0, - 4.4, - 4.6; IR (CHCl3) 
3041, 3948, 2196, 1713, 1485, 1310, 1022 cm-l; MS 
(EI--) m/e calcd for C29H37NO5Si: 507.2441, found 
507.2405; Base 318, Parent 5.08. 
5 R=CH2CH2Cl (71% yield) 
Rf 0.33 (10% etherpentane); 1H NMR (300 MHz, 
CDCl3) 67.62 (bs, 1H), 7.17-6.95 (m, 3H), 5.80–5.66 (m, 
4H), 4.79 (s, 1H), 4.60-4.23 (m, 4H), 3.89-3.62 (m, 3H0, 
3.59-3.44 (m, 1H), 2.83-2.51 (m, 6H), 0.97 (s, 9H), 0.29 
(s, 3H), 0.27 (s, 3H); 13C NMR (75 MHz, CDCl3) 
8153.0, 131.2, 128.2, 125,3, 125.3, 125.0, 124.9, 119.9, 
1.18.9, 103.1, 96.8, 93.1, 82.6, 80.6, 67.4, 65.9, 61.9, 54.6, 
49.3, 41.6, 41.0, 30.2, 25.6, 25.5, 25.3, 19.0, 18.1, 15.2, 
- 4.4, -4.8. 
5 R=adamantyl (64% yield)). 
Rf 0.21 (95:5-pentane: ether); 1H NMR (300 MHz, 
CDCl3) 67.56-7.55 (bm, 1H), 7.09-6.97 (m, 3H), 
5.76-5.68 (m, 4H), 4.75 (bs, 1H), 4.35-4.19 (q, 2H), 3.87 
(m, 1H), 3.57 (M, 1H), 2.17 (s, 9H), 1.83-1.52 (m, 12H), 
97 (s, 9H), 26 (s, 3H), 0.25 (s, 3H); 13C NMR (75 MHz, 
CDCl3) 81519, 150.1, 131.6, 129.0, 127.7, 126.9, 125.2, 
124.9, 1.24.8, 124.3, 119.5, 119.3, 103.5, 96.9, 93.1, 92.9, 
82.7, 81.9, 80.2, 61.9, 54.7, 48.9, 41.5, 36.2, 31.0, 30.1, 
25.6, 19.1 - 4.4, -4.7; IR (CDCl3). 2973, 2956, 2196, 
1702, 1655, 1489, 1244 cm-l; MS (CI+) m/e calc'd for 
C38H49NO5Si: 627.3380, found 627.3389; Base 544, Par 
ent 628. 
Removal of the Tetrahydropyranyl Protecting group 
from 5 to give 6. 
A solution of the THP protected adduct 51.34 g (2.64 
mmol) and TsCH-H2O 0.15 g in ethanol (30 ml) was 
stirred at 55° C. overnight. The mixture was concen 
trated in vacuo, redissolved in ether, washed with aque 
ous sodium bicarbonate, brine, dried (MgSO4) and fil 
tered. The filtrate was concentrated in vacuo and chro 
matographed over silica gel eluting with 40% ether/- 
pentane to give the deprotected alcohol 6 (0.976 g, 
87%). 
6 R=Me (84% yield). 
M. p. 101-102 C.; 1H NMR (300 MHz, CDCl3 87.58 
(bs, 1H), 7.11-7.02 (s, 3H), 5.79 (bs, 1H), 5.78-5.70 (m, 
2H), 5.68 (s, 1H), 4.26 (s, 2H), 3.82 (s, 3H), 2.19 (bs, 1H) 
0.98 (s, 9H), 0.28 (s, 3H), 0.27 (s, 3H); 13C NMR (75 
MHz, CDCl3) 8154.3, 1504, 130.9, 127.7, 125.3, 125.2, 
124.7, 123.7, 120.1, 119.2, 103.0, 95.4, 92.6, 82.4, 80.6, 
53.4, 51.2, 49.3, 24.4, 18.0, -4.40, - 4.83; IR (CHCl3) 
3449, 3051, 2965, 2930, 2896, 2997, 2205, 1704, 1656, 
1570, 1492, 1462, 1436, 1371, 1327, 1306, 1250, 1172, 
1025 cm l; MS m/e calc'd for C24H29NO4Si: 423.1866, 
found 423.1883. 
6 R=CH2CH2Cl (64% yield)). 
Rf 0.31 (50:50-etherpentane); 1H NMR (300 MHz, 
CDC1387.64-7.62 (bs, 1H), 7.16-7.00 (m, 3H), 5.79-5.70 
(m, 4H), 4.58-4.52 (m, 1H), 4.42-4.36 (m, 1H), 4.26 (s, 
2H), 3.77-3.69 (m, 2H), 0.97 (s, 9H), 0.27 (s, 3H), 0.26 (s, 
3H); 13C NMR (75 MHz, CDCl3) 8154.3, 127.8, 125.3, 
125.0, 124.0, 120.2, 119.4, 103.2, 5.3, 82.6, 66.1, 66.0, 
65.9, 51.4, 49.4, 41.7, 25.5, 18.1, 15.3, -4.3, -4.7; IR 
(CHCl3)3495, 3017, 2957, 2058, 1701, 1654, 1174 cm-l; 
MS (CI+) m/e calc'd for C25H30NO4SiCl: 471.1632, 












6 R=adamantyl (78% yield). 
Rf 0.36 (50:50-etherpentane); 1H NMR (300 MHz, 
CDC1=ls) 87.58 (bs, 1H), 7.11-6.98 (m, 3H), 5.78-5.69 
(m, 3H), 4.25 (s, 2H), 2.61 (s, 9H), 2.17 (s, 6H), 0.97 (s 
3H), 0.26 (s, 3H); 13C NMR (75 MHz, CDCl3) 6168.2, 
131.6, 127.7, 12.5.3, 124.3, 119.9, 119.8, 119.0, 103.5, 95.2, 
93.2, 82.6, 82.2, 80.3, 51.4, 48.9, 41.5, 36.1, 30.9, 25.6, 
18.2, -4.4, -4.67; IR (CHCl3) 3460,2918, 1689, 1489, 
1335, 1247, 1050 cm-l; MS m/e calc'd for 
C33H42NO4Si: 544,2883, found 544.2876. 
Complexation of 6 with dicobaltoctacarbonyl to give 7. 
A 100 ml round bottom flask was charged with alco 
hol 6 (1.0g, 2.36 mmol) and 50 ml of ethyl acetate. The 
mixture was cooled to 0 C. followed by the: rapid 
addition of Co2(CO)8 (0.89 g, 1.1 eq) as a solid. Immedi 
ate evolution of gas was observed. The mixture was 
stirred for 15 minutes and then concentrated to dryness. 
The crude product was chromatographed over silica 
(200 times the original weight of starting material) and 
eluted with 20% ether/pentane. 
7 R=Me (47% yield). 
1H NMR (300 MHz, CDCl3) 87.90 (bs, 1H), 7.02 
(6.96, J =m Hz, 1H), 6.88-6.81 (m, 2H), 6.23 (bs, 1H), 
6.11 (d, J = 10.6 Hz, 1H), 5.17 (dd, J = 10.6, 2.3 Hz, 1H), 
4.87 (q, J = 18.2, 5.4 Hz, 2H), 3.36 (s, 3H), 1.93 (bs, 1H), 
0.95 (s, 9H), 0.18 (s, 3H), 0.16 (s, 3H); 13C NMR (75 
MHz, CDCl3) 8.1994-198.7, 1542, 150, 138.3, 130.9, 
127.7, 125.6, 125.5, 125.0, 123.9, 109.8, 103.2, 97.5, 95.3, 
81.6, 81.5, 64.08, 53.6, 49.6, 25.5, 18.2, -4.35, 4.73; 
-4.73; IR (CHCl3) 2957, 2930, 2865, 2093, 2085, 2031, 
1702, 1660, 1557, 1523, 1441, 1377, 1313, 1255, 1178, 
1026, 834 cm l; MS m/e calc'd for C30H29NO10SiCo2 
(M---OH): 693.0276, found 693.0341. 
7 R=CH2CH2Cl (56% yield). 
Rf 37 (8020-pemane:ether); 1H NMR (75 MHz, 
CDCl3) 6 7.63 (bs, 1H), 7.18-7.02 (m, 3H), 6.69 (d, 
J=9.15 Hz, 1H), 5.82 (s, 1H), 5.73 (s, 1H), 5.61 (d, 
J=9.4 Hz, 1H), 4.80-4.52 (m, 4H), 4.41 (bs, 1H), 3.79 
(bs, 2H), 1.99 (s, 9H), 0.27 (s, 3H), 13C NMR (300 MHz, 
CDCl3)61990.198-0, 152.7, 138.4, 127.8, 125.6, 125.5, 
125.2, 125.1, 109.7, 103.3, 100.9, 99.9, 95.0, 81.7, 66.1, 
66.0, 49.9, 41.7, 29.2, 25.5, 18.1, 16.4, -4.3, -4.7. 
7 R=adamamyl (60% yield). 
Rf 30 (80:20-pemane:ether); 1H NMR (300 MHz, 
CDCl3) 87.61-7.54 (bd, 1H), 7.19-7.02 (m, 3H), 6.71 (d, 
J=9.2 Hz, 1H), 5.83 (s, 1H), 5.76 (s, 1H), 5.63 (dd, 
J=9.2, 2.3 Hz, 1H), 4.82-4.60 (m, 2H), 2.17 (s, 9H), 1.72 
(s, 6H), 0.97 (s, 9H), 0.27 (s, 3H); 13C NMR (75 MHz, 
CDCl3)61990-198.8, 151.9, 149.9, 138.2, 1314, 127.6, 
125.5, 125.1, 124.4, 124.3, 110.0, 103.6, 97.6, 95.9, 82.3, 
81.7, 81.3, 64.1, 49.0, 41.4, 36.1, 20.9, (25.5), 18.1, -4.4, 
-4.7; IR (CHCl3) 3215, 2863, 2605, 2030, 1963, 1490, 
1297 cm-l; MS (FAB-) m/e Base 171, parent 828. 
General Procedure for the Cyclization of 7 to give 8. 
To a cooled mixture of 1-nitropropane (20 ml), cobalt 
complexed alcohol 7 (0.80 g, 1.06 retool) and 2,6-di-t- 
butyl-4-methylpyridine (DBMP) (1.29 g, 6.30 mmol) 
was rapidly added triflic anhydride (Tfa0) (0.54 ml, 
3.18 mmol). The mixture was stirred at -10 C. for 15 
min followed by the addition of NaHCO3 (sat), the 
layers were separated, and the aqueous layer extraction 
with diethyl ether (3x25 ml), dried MgSO4). The or 
ganic layer was filtered and concentrated in vacuo fol 
lowed by chromatography over a silica gel column 
eluting with 20% ether:pentane to give the product 8 
(0.333 g, 545/0). 
8 R=Me (54% yield)). 
5,442,065 
11 
Rf 30 (20:80 ether-pemane); H NMR (300 MHz, 
CDCl3) 87.65 (d, J = 8.15 Hz, 1H), 7.36-7.30 (m, 1H), 
7.23-7.17 (m, 2H), 6.92 (d, J =9.8 Hz, 1H), 5.63 (dd, 
J=9.8, 2.5 Hz, 1H), 5.12 (d, J=0.9 Hz, 1H), 4.53-4.44 
(AB, J = 11.2 Hz, 1H), 3.93 (s, 3H), 3.88-3.8 (dd, 
J = 11.2, 4.12 Hz, 1H), 3.60-3.53 (dd, J = 15.3, 4.1 Hz, 
1H); 13C NMR (75 MHz, CDCl3) 8 1990-198.8, 193.7, 
153.6, 143.7, 136.2, 128.9, 128.3, 127.2, 125.9, 123.4, 
108.8, 92.3, 92.0, 90.6, 81.7, 56.6, 54.9, 53.6, 40.2; IR 
(CHCl3). 2943, 2919, 2848, 2896, 2061, 2038, 2026, 1713, 
1601, 1484, 1454, 1437, - 1372, 1343, 1320, 1290, 1261, 
1243, 1155, 1055, 908 cm l; MS m/e calc'd for 
C22H13NO7Co2 (M---2CO): 520.9365, found 520.9356. 
General Procedure for Oxidative Decomplexation of 8 
to give 9. 
To a cooled (-10 C.) mixture of acetone (10 ml) and 
cobalt-complex 8 0.0756 g (0.130 mmol) was added in 
three portions (over 3 minutes) ceric ammonium nitrate 
(CAN) (0.214 g, 0.039 mmol). The mixture was stirred 
for an additional 15 minutes, with rapid evolution of gas 
occurring. The crude mixture was poured onto a fritted 
filter with silica (10 g) and celite 454(R) (5.0 g) eluting 
with 200 ml of ether. The ether layers were concen 
trated and the crude product chromatographed over 
silica gel eluting with 50% ether:pentane to give the 
product 9 (016g, 42%). 
9 R=Me (42% yield). 
M.p. Decomposes at 150° C.; 1H NMR (300 MHz, 
CDCl3)67.56 (d, J = 7.6 Hz, 1H), 7.35-7.26 (m, 3H), 5.88 
(s, 1H), 5.79-5.62 (AB, 9.5 Hz, 2H), 3.84 (s, 3H), 
3.75-3.72 (m, 1H), 3.55-3.45 (m, 1H), 3.34–3.26 (m, 1H); 
13C NMR (75 MHz, CDCl3) 81984, 153.9, 135.7, 128.4, 
127.5, 126.5, 126.3, 126.1, 125.7, 121.2, 99.3, 91.8, 89.2, 
82.6, 54.4, 53.07, 49.2, 21.6; IR (CHCl3) 3032, 3011, 
2958, 2928, 2855, 2207, 1737, 1711, 1583, 1494, 1459, 
14.43, 1371, 1323, 1293, 1247, 1195, 1160, 1137, 1118, 
1098, 1058, 1042, 1027,979 cm-l; MS m/e calc'd for 
C18H13NO3 (M--): 291.0895, found 291.0888. 
General One Pot Procedure for Converting 7 into 9. 
To a cooled mixture of 2-nitropropane (39.0 ml), 
cobalt complexed alcohol 7 (0.913 g, 1.10 mmol) and 
2,6-di-t-butyl-4-methylpyridine (DBMP) (1.13 g, 5.50 
mmol) was rapidly added triflic anhydride (TfG) (0.56 
ml, 3.30 mmol). The mixture was stirred at -10° C. for 
15 min followed by the addition of NaHCO3 (sat), the 
layers were separated, and the aqueous layer extracted 
with 2-nitropropane (3X 10 ml) and dried (MgSO4). 
The organic layers were filtered and diluted with an 
additional 70 ml of acetone, cooled to -10 C., fol 
lowed by the addition of ceric ammonium nitrate 
(CAN) (4.82 g, 8.80 mmol) in three portions (over 5 
minutes). The reaction was stirred for an additional 15 
minutes with rapid evolution of gas occurring, the addi 
tion of Hunig's base 4.80 ml (27.5 mmol) resulted in the 
formation of a brown precipitate. The crude reaction 
mixture was poured onto a frit of silica (50 g) and eluted 
with ethyl acetate (500 ml). The organic layers were 
concentrated and the crude product chromatographed 
over silica gel eluting with dichloromethane to give the 
product 9 (0.247 g, 55%). 
9 R=CH2CH2Cl (24% yield). 
Rf 62 (50:50-etherpemane); 1H NMR (300 MHz, 
CDCl3) 87.59 (d, 1H), 7.36-7.25 (m, 3H), 5.88 (s, 1H), 
5.79-5.76 (d, J =9.46 Hz, 1H), 5.64-5.61 (d, J =9.72 Hz, 
1H), 4.39 (m, 1H), 3.78 (m, 2H), 3.56 (m, 2H), 3.31-3.23 
(m, 1H); 13C NMR (75 MHz, CDCl3) 8.198.1, 153.8, 
135.3, 128.3, 127.5, 126.5, 126.3, 126.2, 125.7, 121.1, 99.2, 













2957, 2927, 2205, 1737, 1711, 1398, 1285 cm-1; MS m/e 
calc'd for C19H4NO3Cl: 339.0662, found 339.0663. 
9 R=adamantyl (55% yield). 
R?. 46 (50:50-etherpentane); 1H NMR (300 MHz, 
CDCl3) 87.55 (d, J = 7.31 Hz, 1H), 7.29-7.21 (m, 3H), 
5.82 (s, 1H), 5.75 (d, J =9.3 Hz, 1H), 5.63 (d, J =9.6Hz, 
1H), 3.71 (bs, 1H), 3.54-3.50 (m, 1H) 3.48-3.20 (dd, 
J - 14.5, 2.97 Hz, 1H), 2.15 (s, 9H), 1.6 13C NMR (75 
MHz, CDCl3)8198.9, 151.7, 136.1, 128.2, 127.2, 126.3, 
126.2, 125.8, 125.6, 121.2, 99.3, 91.489.7, 83.3, 82.7, 49.1, 
41.4, 36.2, 36.0, 30.9, 21.5; IR (CHCl3)3013, 2917, 2341, 
1736, 1698, 1364, 1048 cm-1; MS (CI--) m/e calc'd for 
C27H25NO3: 411.1834, found 411.1825; parent 411, Base 
153. 
Deprotection of the Adamanty Carbamate 9 to give 12. 
To a solution of carbamate 9 (0.247 g. 0.60 mmol) in 
10 ml of dichloromethane, was 2.31 ml (30.0 mmol) of 
trifluoroacetic and the mixture stirred for 2 hours. The 
mixture was quenched by the addition of NaHCO3 and 
extracted with dichloromethane (3x25 ml). The result 
ing organic extracts were dried over MgSO4, filtered, 
concentrated in vacuo and chromatographed over silica 
gel eluting with dichloromethane to give 0.140 g (81% 
yield) of 12. 
12. Rf 0.50 (50:50-ether:pentane); 1H NMR (300 
MHz, CDCl3) 87.25-7.22 (d, J =9.67 Hz, 1H), 7.15 (t, 
J=7.47 Hz, 1H), 6.95 (t, J = 7.48 Hz, 1H), 6.74 (d, 
J=7.87 Hz, 1H), 5.73 (q, J=22.4, 9.11 Hz, 2H), 4.62 (s, 
1H), 4.23 (bs, 1H), 3.63 (t, J =4.08 Hz, 1H), 3.51 (dd, 
J=2.88 Hz, 1H), 3.39 (qd, J = 17.72, 4.78, 1.70 Hz, 1H); 
13C NMR (75 MHz, CDCl3) 8199.6, 1424, 127.9, 126.6, 
125.8, 122.3, 121.3, 120.9, 116.5, 100.1, 92.7, 90.0, 83.0, 
540, 53.4, 21.7; IR (CH2Cl2) 3379, 2986, 2305, 1733, 
1422, 1265, 896 cm-l; MS m/e calc'd for C16H2NO: 
233.0840, found 233.0834. 
6-Methoxy-3-nitroquinoline 14. 
p-Anisidine hydrochloride (35.0 g, 219.4 mmol) was 
weighed into a dry 300 mL three-necked round-bot 
tomed flask, equipped with a magnetic stirring bar, a 
pressure-equalizing addition funnel, a solid addition 
funnel and a thermometer. Glacial acetic acid (150 mL) 
was added to the solid, with vigorous stirring to main 
tain a homogeneous suspension. To this suspension was 
added sodium nitromalonaldehyde monohydrate (12.0 
g, 76.4 mmol) and the mixture stirred for 1.0 hat 25 C. 
A short-path distillation head was placed on the flask 
and approximately 120 mL of acetic acid/water re 
moved under reduced pressure at 40° C. To the residue 
(imine 13) was added glacial acetic acid (40 mL) and 
sulfolane (75 mL). The resulting solution was flushed 
with argon to remove air and the flask immersed in an 
oil bath preheated to 195 C. The mixture was vigor 
ously stirred while acetic acid was removed by distilla 
tion. When the temperature reached 184-185° C. the 
mixture was stirred for a further 15 min at 185 C. and 
then poured (while still at ca. 180° C) onto crushed ice 
(750 g). The resulting solution was allowed to stand in 
a refrigerator (overnight) until precipitation was com 
plete. The dark brown solid precipitate was filtered and 
transferred to a round-bottomed flask (500 mL) contain 
ing 2M hydrochloric acid (250 mL). The mixture was 
heated at reflux for 50-60 min and the boiling; solution 
filtered through a preheated Bichner funnel to remove 
an insoluble brown gum. The hot filtrate was cooled to 
ca. 4 C. and extracted with chloroform (4X50 mL). 
The combined extracts were dried (MgSO4) and the 
chloroform removed on a rotatory evaporator to give 
5,442,065 
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the crude 3-nitro-6-methoxyquinoline 14 (9.3 g, brown 
solid). 
The crude quinoline was dissolved in boiling 95% 
ethanol (ca. 125 mL) and the hot solution was carefully 
treated with decolorizing carbon (ca. 3.0 g). The hot 
solution was then filtered through a cake of celite, 
which was then washed with boiling ethanol (5.10 mL). 
The hot solution was allowed to cool slowly to room 
temperature and then placed in the freezer overnight. 
The light brown, fine crystals were filtered off, washed 
once with chilled ethanol (12 mL) and then dried in a 
desiccator under high vacuum to give 3-nitro-6-methox 
yguinoline 14 (4.72 g, 30.25% yield). 
The mother liquor was concentrated and the result 
ing brown solid (ca. 3.0 g) chromatographed on SiO2 
(100 g. flash) with 20% ethyl acetate in hexanes as elu 
ant (chloroform can also be used as eluant). The result 
ing 1.58 gms of product were recrystallized from 95% 
ethanol (as above) yielding 0.91 gins of product (5.83% 
yield). Overall yield based on sodium nitromalonalde 
hyde monohydrate was 36.08%. 14. M. p. 133-135 C.; 
1H NMR (300 MHz, CDCl3) 89.5 (d, J =24 Hz, 1H), 
8.92 (d, J =24 Hz, 1H), (d, J =9.1 Hz, 1H), 7.57 (dd, 
J=2.79.1 Hz, 1H), 7.24 (d, J =2.7, Hz, 1H 3.99 (s, 1H); 
13C NMR (75 MHz, CDCl3) 8159.3, 146.4, 1414, 141.3, 
131.0, 130.5, 127.4, 126.4, 106.3, 55.8; IR (CHCl3) 3075, 
3015, 2965, 2940, 1624, 1612, 1577, 1543, 1500, 1466, 
1428, 1378, 1360, 1232, 1029 cm-l; MS (CI) m/e calcu 
lated for C10H9N2O3: 205.061, found 205.0613, base 
peak 205, parent peak 205, 188, 158, 154; Anal calcd for 
CoH8N2O3: C, 58.82%; H, 3.95%; N, 13.72%; Found: 
C, 58.78%; H, 3.87%; N, 13.50%. 
Alternative Procedure. 
A 250 ml 3-neck round bottom flask (equipped with 
condenser/argon inlet, magnetic stirrer and thermome 
ter) was charged with the enamine 13 (8.0 g, 36.0 
immoles) and p-anisidine hydrochloride (11.48 g, 
72.mmoles) and glacial acetic acid (72 mL) added. The 
flask was purged with a stream of argon and the mixture 
was stirred and heated to reflux (ca. 116 C.). The sus 
pension became a dark brown solution at ca. 90° C. The 
solution was heated at reflux for approximately 80 min. 
A catalytic amount of 3,5-dimethylthiophenol (0.995 g, 
7.2 mmole) was added and the mixture heated at reflux 
for 50 hours. The progress of the reactions can be fol 
lowed by tic (SiO2, 20% ethyl acetate in hexanes, three 
developments). 
After 50 hours the reaction mixture was allowed to 
cool to room temperature and the acetic acid removed 
by rotary-evaporation under oil pump vacuum (bath at 
ca. 55 C.). The dark brown residue was heated at reflux 
with 2M HCl (200 mL) for 30-50 min. The hot aqueous 
solution was filtered through a Buchner funnel (brown 
gum-insoluble in hot HCI was discarded after tic indi 
cates only minimal amount of the product was present) 
cooled to 4° C. and extracted with chloroform (4x50 
mL). The combined organic extracts, were dried 
(MgSO4) and the solvent removed by rotary evapora 
tion and high vacuum. The crude product was purified 
by recrystallization from boiling 95% EtOH and col 
umn chromatography (20% EtO Ac-hexanes) of the 
mother liquor concentrate on SiO2. Total yield of puri 
fied product 14 was 3.55 g (48.3%). 
Preparation of Enamine 13: 
p-Anisidine hydrochloride (12.8 gms. 80.0 mmol) was 
dissolved in 2M HCI (32 mL) and the stirred solution 
diluted with water (35 mL). To this solution was added, 










monohydrate (1) (10.04 gms, 64.0 mmoles) Org. Syn. 
Col. Vol. IV, 844, ca. 64.0 mmol) dissolved in water (80 
mL). A yellow precipitate formed instantaneously and 
the thick mixture was stirred with a glass rod. After ca. 
20 min. at room temperature the precipitate was filtered 
on a Buchner funnel, the press cake washed with dis 
tilled water (1X80 mL), air dried for 3 hours and then 
suspended in ether as a thick slurry. Filtration, followed 
by air drying on the Buchner gave the enamine 13, 
which was further dried over P2O5 (desiccator under 
vacuum overnight). Yield: 10.7 to 12.1 gms (7585%). 
6-Methoxy-3-aminoquinoline 15 
21.2 g (0.104 mole) of the nitroquinoline 14 was added 
portionwise to a 1.0 L beaker containing 320 mL conc. 
HCI at 50 C., with vigorous stirring. Then the heating 
bath was removed and 71.0 g of SnCl2.2H2O (0.312 
mole, finely ground) was added portionwise over 2-3 
min (the temperature of the mixture reached 80 C.). 
The mixture was stirred vigorously for i0 min, and 
diluted with water to 1.0 L. The pH was adjusted to 9 
using 5M NaOH (900-950 mL) and the aqueous layer 
(2.0 L) was cooled to 4. C., and extracted with EtOAc 
(3X500 mL). The combined organic layers were 
washed with ice-cold water (200 mL), brine (400 mL) 
and dried over anhydrous MgSO4. Filtration and re 
moval of the solvent in vacuo gave 17.6 g of crude 15. 
The crude product was vigorously stirred with 50 mL. 
CHCl3 and the tan microcrystalline solid forming was 
filtered on a sintered glass funnel. The precipitate was 
washed with CHCl3 (2x25 mL) and then air dried. 
Removal of the last traces of solvent in vacuo gave 8.1 
g of product. The washings were combined with the 
filtrate, concentrated by rotovap and placed in the 
freezer. Two more crops of 15 were thus obtained (3.8 
and 2.3 g). The mother liquor concentrate was purified 
by column chromatography on silica gel (EtOAc-hex 
anes 1:1) and a further 1.3 g of product 15 was obtained 
(overall yield 15.5g, 86%). A small amount of 4-chloro 
6-methoxy-3-aminoquinoline (5%) was also obtained as 
a less polar byproduct. 
151H NMR (300 MHz, CDCl3) 88.33 (d, J =2.7 Hz, 
1H), 7.84 (d, J =9.1 Hz, 1H), 7.13 (d, J = 2.6 Hz, 1H), 
7.10 (dd, J =2.6, 9.1 Hz, 1H), 6.85 (d, J = 2.7 Hz, 1H), 
3.92 (s, 3H), 3.50 (br, 2H); 13C NMR (75 MHz, CDCl3) 
8158.1, 140.4, 140.1, 138.7, 130.4, 130.2, 118.0, 114.2, 
103.6, 55.3; MS (CI) m/e calcd for C10H10N2O: 174,079, 
Found 174,079; base peak 175, parent peak 175. 
3-Hydroxy-6-methoxy quinoline 16. 
17.4 g (0.1 mole) of the aniline 15 was dissolved in 335 
mL 2N HCl and the mixture was diluted with 280 mL 
water and cooled to 4 C. Addition of 7.5 g (0.109 mole) 
NaNO2 in 70 ml water followed by stirring at 4 C. for 
two hours gave a solution of the diazonium salt 15a. 
This solution was added to a vigorously stirred solution 
of 161 mL conc. H2SO4 and 385 mL water at 85°-90° C. 
(addition time 1 hour). The resulting solution was 
stirred at 90-95 C. for an additional hour, cooled to 
room temperature, neutralized with solid NaHCO3, 
cooled to 0°C. and extracted with EtOAc (3X800 mL). 
The combined organic layers were dried (MgSO4) fil 
tered and the solvent removed in vacuo. The crude 16 
thus obtained (16.6 g., 95% yield) was used directly in 
the next step. 16 H NMR (300 MHz, DMSO 
d6/CDCl3) 89.60 (br, 1H), 8.36 (d, J =2.6 Hz, 1H), 7.72 
(d, J =9.1 Hz, 1H), 7.27 (d, J =2, 6 Hz, 1H), 7.01 (dd, 
J=2.7, 9.1 Hz, 1H), 6.85 (d, J =2.7 Hz, 1H), 3.80 (s, 3H); 
13C NMR (75 MHz, DMSO-d6) d 157.7, 1514, 141.1, 
138.5, 130.5, 130.0, 118.3, 114.8, 104.5, 55.3; MS (CI) 
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m/e calcd for C10H9NO2; 175.063, Found 175.064; base 
peak 176, parent peak 176, 159, 157, 141, 119. 
3-(tert-butyldimethylsilyloxy)-6-methoxyquinoline 
17. 
A 500 mL flask, equipped with magnetic stirrer and 
septum, was charged with 16.6 g crude 16 (0.095 mole), 
22.1 g TBDMS-Cl (97%, 0.142 mole), 13.1 g imidazole 
(99%, 0.19 mole) and 240 mL DMF (distilled, added by 
syringe). The mixture was stirred under argon for 8 
hours and then poured into 1.0 L of water and extracted 
with ether (3X450 mL). The combined organic extracts 
were dried (MgSO4), filtered and the solvent removed 
in vacuo to give 36.4 g of crude (orange solid). Crystal 
lization from Et2O-pentane (1:9) and chromatography 
of the mother liquor concentrate on silica gel (Et2O 
pentane 1:2) gave 25.0 g of 17, 91% yield. 
17 M.p. 59°-61° C.; 1H NMR (300 MHz, CDCl3) 
88.40 (d, J =2.5 Hz, 1H), 7.91 (d, J =9.2 Hz, 1H), 7.32 
(d, J = 2.6 Hz, 1H), 7.20 (dd, J = 2.7, 9.2 Hz, 1H), 6.9 (d, 
J= 2.7 Hz, 1H), 3.95 (s, 3H), 1.02 (s, 6H), 0.12 (s, 6H); 
13C NMR (75 MHz, CDCl3) 8158.0, 149.6, 143.9, 139.8, 
130.3, 130. 1, 120.6, 119.6, 104.2, 55.3, 25.5, 18.3, -4.5; 
MS (CI)m/e calculated for C16H23NO2Si: 289.149, 
found 289.150; base peak 290, parent peak 289,232, 137, 
135, 133, 113; Anal calcd for C16H23NO2Si: C, 66.39%; 
H, 8.01%; N, 4.84%; found: C, 66.17%; H, 8.06%; N, 
4.62%. 
Coupling quinoline 17 and enediyne 18 to give 19. 
A solution of ethylmagnesium bromide in THF (43 
ml 1M solution, 43.3 mmol) was added to a solution of 
z-hept-4-ene-2,6-diyn-1-ol tetrahydropyranyl ether 18 
(6.89 g, 36.2 mmol) and 6-methoxy-3-(tert-butyldime 
thylsiloxy)-quinoline 17 (9.41 g, 32.5 mmol) in THF 
(210 ml) cooled to 0°C. After the initial evolution of gas 
the reaction mixture was stirred for 20 minutes at 0° C. 
and a solution of adamantyl chloroformate (11.51 g, 
53.6 mmol) in THF (40 ml) was added via syringe pump 
over 90 minutes while maintaining the temperature at 0° 
C. On completion of the addition, the reaction mixture 
was allowed to warm to room temperature and stirred 
for 18 hours before quenching with saturated aqueous 
sodium bicarbonate solution (60 ml). The resulting mix 
ture was extracted with ether (1x300 ml, 2x 150 ml), 
the combined organic extracts dried over magnesium 
sulphate and evaporated to give a brown oil. Flash 
column chromatography on silica gel eluting with 80% 
pentant, 20% diethylether yielded 16.11g, (75%) of the 
desired product 19 as a clear yellow oil. H NMR (300 
MHz, CDCl3) 87.43 (s, 1H), 6.62 (dd, J = 8.8, 2.8 Hz, 
1H), 6.52 (d, J =2.8 Hz, 1H), 5.74 (dd, J = 11.0, 1.4 Hz, 
1H), 5.68-5.79 (s, 1H), 5.67 (d, J = 11.0 Hz, 1H 5.62 (s, 
1H), 4.75 (s, 1H), 4.31 (dd, J = 16.0, 1.4 Hz, 1H), 4.23 
(dd, J = 16.0, 1.4 Hz, 1H), 3.77-3.89 (m, 1H), 3.76 (s, 
3H), 3.46-3.58 (m, 1H), 2.15 (s, 9H), 1.64 (s, 6H), 
1.45-1.89 (m, 6H), 0.96 (s, 9H), 0.25 (s, 3H), 0.24 (s, 3H); 
13C NMR (75 MHz, CDCl3) 8156.3 (e), 152.0 (e), 128.9 
(c), 125.5 (o), 124.8 (e), 119.5 (o), 119.3 (o), 110.5 (o), 
109.9 (o), 103.5 (o), 96.8 (o), 93.1 (e), 92.8 (e), 82.7 (e), 
81.6 (e), 80.1 (e), 61.9 (e), 55.3 (o), 54.7 (e), 48.8 (o), 41.5 
(e), 36.1 (e), 30.9 (o), 30.2 (e), 25.5 (o), 25.3(e), 1.9.0 (e), 
18.1 (e), -4.3 (o), - 4.7 (o); IR (CHCl3) 1687 cm-1; 
MS (FAB) m/e calculated for C39H51NO6Si: 657.349, 
found 657.351. 
Removal tetrahydropranyl ether to give 20. 
Pyridinium p-toluenesulphonate (1.23g, 4.9 mmol) 
was added to a solution of the tetrahydropyranyl ether 
19 (16.1 g, 24.5 mmol) in ethanol (320 ml) at room tem 













After cooling the solution to room temperature the 
solvent was removed under reduced pressure, and 
water (150 ml) added to the residue. Extraction with 
diethylether (1X200 ml, 2x 100 ml) drying of the com 
bined organic layers over magnesium sulphate and 
evaporation gave the crude product as a viscous dark 
brown oil. Flash column chromatography on silica gel 
eluting with 60% pentane, 40% diethylether (Rf 0.40) 
yielded 12.58 g (89%) of the desired product 20 as a 
yellow-green amorphous solid. Alternatively the prod 
uct was obtained from the crude by crystallization (20% 
ether-80% pentane, 50 ml, 12.15 g, 86% yield). H 
NMR (300 MHz, CDCl3)87.44 (s, 1H), 6.63 (dd, J = 8.9, 
2.7 Hz, 1H), 6.52 (d, J = 2.7 Hz, 1H), 5.77 (m, 1H), 
5.70-5.80 (m, 1H), 5.68 (n, 1H), 5.64 (s, 1H), 4.27 (s, 
2H), 3.77 (s, 3H), 2.15 (s, 9H), 1.64 (s, 6H), 0.96 (s, 3H), 
0.26 (s, 3H), 0.25 (s, 3H); 13C NMR (75 MHz, 
CDCl3)6156.3 (e), 152.2 (e), (e), 125.3 (o), 124.8 (e), 
119.9 (o), 119.6 (o), 110.5 (o), 109.9 (o), 103.6 (o), 95.3 
(e), 93.2 (e), 82.5 (e), 81.9 (e), 80.2 (e), 55.3 (o), 51.3(e), 
48.9 (o), 41.5 (e), 36.1 (e), 30.9 (o), 25.5 (o), 18.1 (e), 
- 4.33 (o), - 4.71 (o); IR (CHCl3) 3474, 1685, 1653 
cm-l; MS (FAB) m/e calculated for C34H43NO5Si: 
579.291, found 573.290. 
Cobalt complexation of 20 to give 21. 
A solution of dicobalt octacarbonyl (2.67 g, 7.81 
mmol) in THF (60 ml) was added rapidly in a single 
portion to a stirred solution of the propargylic alcohol 
20 (4.27g, 7.44 mmol) in THF (80 ml) at room tempera 
ture. After the initial evolution of gas the reaction mix 
ture was stirred at room temperature for 40 minutes 
then evaporated to give a viscous brown oil. Flash 
column chromatography on silica gel sequentially elut 
ing with 90% pentane, 10% diethylether gave first a 
trace of the bis-cobalt complex 23 as a black amorphous 
solid followed by the desired cobalt regeoisomer 213.77 
g (59%) as a red-brown amorphous solid. Further elu 
tion with 70% pentane, 30% diethyl ether yielded the 
undesired cobalt regeoisomer 22 2.02 g (33%) as a red 
brown amorphous solid. Finally elution with 60% pen 
tane, 40% diethylether gave 0.25 g (6%) of the recov 
ered propargylic alcohol. 20. For 21 H NMR (300 
MHz, CDCl3) 67.4 (s, 1H), 6.6-6.72 (m, 2H), 6.54 (d, 
J=2.8, Hz, 1H), 5.80 (s, 1H), 5.66 (s, 1H), 5.62 (rid, 
J = 10.5, 2.0 Hz, 1H), 4.82 (m, 1H), 4.70 (d, J = 14.5 Hz, 
1H), 3.77 (s, 3H), 2.16 (s, 9H), 1.65 (s, 6H), 0.95 (s, 9H), 
0.25 (s, 3H, 0.24 (s, 3H); 13C NMR (75 MHz, 
CDCl3)6156.5 (e), 152.3 (e), 138.2 (o), 128.9 (e), 125.4 
(o), 124.6 (e), 110.7 (o), 110.1 (o), 103.7 (o), 97.7 (e), 96.0 
(e), 82.1 (e), 81.8 (e), 81.2 (e), 64.1 (e), 64.0 (e), 55.4 (o), 
41.5 (e), 36.1 (e), 30.9 (o), 25.5 (o), 18.1 (e), -4.3 (o), 
- 4.7 (o); IR (CHCls) 2092, 2056, 2026, 1687, 1655 
cm-1; UV-Vis (c=0.0036 mg/ml, CHCl3) A max243 nm 
(e=3.3x105). 
Recycling incorrect cobalt regioisomer 22. 
Ceric ammonium nitrate (5.15 g, 9.40 mmol) was 
added portionwise over 3 to 4 minutes to a solution of 
the cobalt complex 22 (2.02 g, 2.35 mmol) and 2,6-di 
tert-butyl-4-methylpyridine (3.86 g, 18.8 mmol) in ace 
tone (24 ml) at -10° C. After an initial evolution of gas 
the reaction mixture was stirred for 20 minutes at -10 
C. and quenched by the addition of diisopropylethyla 
mine (6.07 g., 47.0 mmol). The resulting dark brown 
slurry was eluted through a short column of silica gel 
with 50% diethyl ether, 50% dichloromethane and 
evaporated to give a viscous brown oil. Flash column 
chromatography on silica gel eluted with 60% pentane, 
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40% diethylether (Rf 0.40) yielded 1.03 g (76%) of the 
propargylic alcohol. 20. 
Cyclization of 21 to give the 7.3.1system 24. 
Trifluoromethanesulphonic anhydride (1.71 ml, 10.2 
mmol) was added rapidly in a single portion to a stirred 
solution of the cobalt complex 21 (2.18 g, 2.54 mmol) 
and 2,6-di-tert-butyl-4-methylpyridine (3.13 g, 15.2 
mmol) in 2-nitropropane (55 ml) at -10° C. After stir 
ring for 30 minutes at -10° C. the reaction mixture was 
quenched by the addition of a saturated aqueous solu 
tion of sodium bicarbonate solution and the layers sepa 
rated. Extraction of the aqueous layer with 2-nitropro 
pane (1X 15 ml), drying of the combined organic layers 
over magnesium sulphate, filtration and dilution with 
acetone (80 ml) gave an opaque red brown solution. 
After cooling to -10° C., ceric ammonium nitrate 
(13.93 g, 25.4 mmol) was added portionwise over 3 to 4 
minutes. After the initial gas evolution, the reaction 
mixture was stirred for 20 minutes at -10° C. and 
quenched by the addition of diisopropylethylamine 
(8.85 ml, 50.8 mmol). Elution of the reaction mixture 
through a short column of silica gel with 50% die 
thylether, 50% dichloromethane followed by evapora 
tion gave a viscous brown oil. Flash column chroma 
tography on silica gel eluted with dichloromethane (Rf 
0.50) yielded 0.59 g (53%) of the cyclized enediyne 24 
as a white amorphous solid. Recrystalization from di 
chloromethane-diethylether produced small white 
prisms. IH NMR (300 MHz, CDCl3) 87.44 (d, J-8 Hz, 
1H), 6.81 (dd, J =2.4, 8.9 Hz, 1H), 6.76 (s, 1H), 5.77 (s, 
1H), 5.75 (d, J =9.5, 2.0 Hz, 1H), 5.62 (d, J =9.5 Hz, 
1H), 3.79 (s, 3H), 3.68 (A of ABX, 1H), 3.47 (A of ABX, 
1H), 3.19 (Bof ABX, 1H), 2.13 (s, 9H), 1.64 (s, 6H), 13C 
NMR (75 MHz, CDCl3) 8.198.5 (e), 157.1 (e), 151.8 (e), 
129.5 (e), 129.3 (e), 126.8 (e), 126.3 (e), 121.1 (o), 112.3 
(o), 111.6 (o), 99.1 (e), 91.5 (e), 90.0 (e), 83.3(e), 55.4 (o), 
54.2 (o), 49.2 (o), 41.4 (e), 36.0 (e), 30.9 (o), 21.5 (e); IR 
(CHCl3) 1733, 1696, cm-l; MS FAB m/e calculated for 
C28H28NO4: 442.201, found 442.205; base peak 307, 
parent peak 442,289, 154, 135. 
Removal of adamantyl carbamate to give 25. 
Trifluoroacetic acid (2.1 ml, 27.3 mmol) was added 
dropwise to a stirred solution of the carbamate 24 (481 
mg, 1.09 mmol) in dichloromethane (22 ml) at O C. The 
reaction mixture was allowed to warm to room temper 
ature and quenched by the addition of saturated aque 
ous sodium bicarbonate solution (20 ml) when adjudged 
to be complete by TLC (silica gel, eluted with 50% 
pentane 50% diethylether9 Rfcarbamate 0.50, Rfaniline 
0.40), approximately 90 minutes. Extraction with di 
chloromethane (3X15 ml), drying of the combined 
organic extracts over magnesium sulphate and evapora 
tion gave a brown amorphous solid. Flash column chro 
matography on silica gel eluted with 90% dichloro 
methane, 10% diethyl ether yielded 224 mg (78%) of 
the aniline 25 as a white amorphous solid. INMR (300 
MHz, CDCl3) 86.6-6.8 (m, 3H), 5.78 (d, J =9.2, Hz, 
1H), 5.66 (d, J =9.2 Hz, 1H), 4.58 (s, 1H), 3.76 (s, 3H), 
3.59 (A of ABX, 1H), 3.55 (A of ABX, 1H), 3.22 (B of 
ABX, 1H); 13C NMR (75 MHz, CDCl3) 6199.6 (e), 
153.9 (e), 136.3 (e), 125.6 (o), 123.5 (e), 121.2 (o), 117.0 
(o), 112.9 (o), 112.4 (o), 99.9 (e), 93.2 (e), 89.9 (e), 82.9 
(e), 55.5 (o), 54.2 (o), 48.6 (o), 21.6 (e); MS (FAB) m/e 
calculated for C17H14NO2; 264.102, found 264.102; base 














In vivo testing in mice was performed on two 13 
ketobicyclo 7.3.1tridecaenediyne compounds. Both 
compounds exhibited activity in the P388 leukemia test 
while one additionally showed significant activity in a 
solid tumor assay. 
P388 Leukemia Assay 
In vivo P388 leukemia assays were performed using 
CDF1 female mice. In experiments, approximately 
1X106 cells were injected intraperitoneally (IP). On day 
1 post implant, dose titrations of the compound were 
administered intraperitoneally (IP) on day 1 post im 
plant only. Each of six animals received a single injec 
tion of 64, 32, 16, 8, 4 and 2 mg/kg/dose. Compounds 
5582 and 4229 shown in FIG. 8 were tested and com 
pared with Kedarcidin which was employed as a refer 
ence compound. 
Activity with both compound 5582 and 4229 was 
observed at an optimal dose of 2 mg per kg, yielding 
maximal T/C values of 170% and 175% respectively. 
This compared with kedarcidin which was included as 
a reference compound and which produced a maximum 
T/C of 175% at 2.4 mg per kg. Thus the core enediyne 
dynemicin and its 13-methoxy derivative were active 
and showed good potency in the P388 leukemia assay 
when compared with kedarcidin. Results are shown in 
Table 1. 
TABLE I 
P388 Leukemia Assay 
Compound Dose (mg/kg) % T/C Survivors 
4229 64 toxic 0/6 
32 toxic O/6 
6 60 6/6 
8 65 6/6 
4 65 6/6 
2 170 6/6 
5582 64 toxic 0/6 
32 70 5/6 
16 60 6/6 
8 65 6/6 
4 70 6/6 
2 175 6/6 
kedarcidin 2.4 175 6/6 
1.2 65 6/6 
Solid Tumor Assay 
This assay involves development of a solid tumor in a 
mouse by injection of M109 tumor cells under the skin 
of the animal. Solid tumors, typically elliptical in shape, 
rapidly develop on the flank of the mouse at the site of 
injection. Progress of the tumor is determined by its size 
which is measured across each axis of the elongated 
mass. Straightforward computations of tumor volume 
combined with an assumed density of 1 g per cc yields 
a weight estimate which is accepted as an indication of 
the progress of tumor growth. Increase in lifespan (T/C 
values) of the animal and delay in tumor growth (T-C) 
to reach a predetermined size (typically measured as 
weight of the tumor) are generally accepted by those of 
skill in the art as endpoint parameters. The clinically 
tested compounds neocarzinostatin and esperamicin Ali 
showed increased lifespan and delay in tumor growth, 
providing standard compounds against which new de 
rivatives and analogs were compared. In the particular 
M109 assay described and used to test the novel 
dynemicin analogs, the median time to establish a base 
line tumor burden (arbitrarily set at 1 g tumor) was 4 
5,442,065 
19 
days. Compounds that delayed tumor growth by less 
than 3 days were considered to lack significant activity. 
A standard M109 solid tumor assay was set up to 
compare compound 5582 and 4229 with neocarzinosta 
tin and esperamicin A1. Female mice were injected 
subcutaneously with 0.1 mL of a 0.2% brei of M109 
tumor cells, prepared from 2 g tumor per 100 mL PBS 
(phosphate buffered saline). 
Compound 5582, shown in FIG. 9, was tested in a 
solid tumor assay compared against kedarcidin as a 
reference. Results are shown in Table 2. 
TABLE 2 
Solid Tumor M109 Assay 
Compound Dose (mg/kg/dose) %T/C Survivors 
5582 0.64 106 8/8 
0.32 103 8/8 
0.6 102 8/8 
0.08 97 8/8 
kedarcidin 0.04 108 8/8 
0.03 94 8/8 
0.02 06 8/8 
0.01 102 8/8 
In another test, compounds 5582 and 4229 were eval 
uated in mice implanted with M109 on a 5 injection per 
day every two days schedule beginning on day 1 post 
implant and compared with SC tumored mice. Neocar 
zinostatin, which was included as a positive reference 
compound, produced a T/C value of 19.3 days and 
esperamicin A1 had a T/C of 11 days. Compound 5582, 
while not as active as esperamicin A1, nevertheless 
showed significant activity with a T/C value of 7.5 
days, injected at a dose of 1.2 mg/kg/dose five times 
every two days. Compound 4229, injected at a dose of 
0.4 mg/kg/dose five times every two days produced a 
maximum delay of 3.0 days, indicating only marginal 
activity. 
EXAMPLE 3 
The dynemicin core analogs, compounds 4229 and 
5582 shown in FIG. 9, were tested for in vitro cytotox 
icity. 
In Vitro Cytotoxicity 
The bicyclo 7.3.1tridecaenediyne core structure 
analogs of the antitumor antibiotic dynamicin were 
tested for in vitro cytotoxicity against. Cytotoxicity was 
assessed in HCT116 human colon carcinoma cells by 
XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- 
(phenylamino)carbonyl-2H-tetrazolium hydroxide 
assay (Scudiero, et at., 1988). Cells were plated at 4000 
cells/well in 96 well microtiter plates and 24 hrs later 
drugs were added and serially diluted. The cells were 
incubated at 37 C. for 72 hrs at which time the tetrazo 
lium dye, XTT, was added. A dehydrogenase enzyme 
in live cells reduces the XTT to a form that absorbs 
light at 450 nm which can be quantitated spectrophoto 
metrically. The greater the absorbance the greater the 
number of live cells. The results are expressed as an 
IC50 which is the drug concentration required to inhibit 
cell proliferation (i.e., absorbance at 450 nm) to 50% of 
the absorbance of untreated control cells. 
Table 3 lists these compounds along with their IC50s. 
Structures are shown in FIG. Compound 4229 had an 
IC50 of 0.21 uM while compound 4230, differing only 
by an adamantyl carbamyl substituted at the secondary 
amine group, was less toxic by a factor of over 350, 




















Several derivatives of the core enediyne dynemicin 
have been synthesized. The structure of the core com 
pound has been substituted at R1, R2, R3 and X at the 
positions indicated in FIG. 10. For example, R1 may be 
the usual range of aromatic substitutents such as lower 
alkyl, halogen, O-alkyls, N-alkyls, S-alkyls. R2 may 
include carbamates such as alkyl-OCON, Ar-OCON 
and so forth. R3 is alkyl, including -CH2OMe, SPh, 
SePh and-CH(OH)Ph. The X group is O, CHCN 
(both E and Z), -CH2 and -CHCO2Me. Specific 
synthesis is illustrated. 
X=O, R1 =OMe, R2 = CO2Ad, R3 = SePh 
A solution of lithium hexamethyldisilazane in THF 
(1.0M, 0.48 mL, 0.48 mmol) was added dropwise to a 
cold (-78° C) solution of the carbamate R3 = H (192 
mg, 0.435 mmol) in THF (3.5 mL). The resulting yellow 
solution was stirred under argon for 20 min. The lithium 
enolate was quenched, at -78 C.), by dropwise addi 
tion of a solution of phenyl selenide (98%, 140 mg, 0.58 
mmol) in THF (0.25 mL). Following 15 min stirring at 
-78 C., the cooling bath was removed; aq. Saturated 
NH4Cl (2.0 mL) was added to the cold solution. The 
mixture was diluted with Et2O (8.0 mL), the phases 
separated and the aqueous phase extracted with Et2O 
(2X 6.0 mL). The combined organic phases were dried 
(MgSO4) filtered and the solvent removed in vacuo to 
give the crude product (310 mg). Flash chromatogra 
phy on silica gel (10.0g, 20:80 Et2O-pentane) afforded 
X=O, R1 = OMe, R2 = CO2Ad, R3 = SePh (241 mg, 
93% yield) as a pale yellow amorphous solid. R? 0.36 
(2x20:80-ether:pentane); 1H NMR (300 MHz, CDCl3) 
87.15-7.50 (m, 6H), 6.74 (dd, J = 2.7, 10.0 Hz, 1H), 6.28 
(d, J = 2.7 Hz, 1H), 5.96 (m, 1H), 5.69 (d, J =9.6 Hz, 1 
H), 5.60 (d, J =9.6 Hz, 1H), 3.66 (d, J = 17.4 Hz, 1H), 
3.59 (s, 3H), 3.31 (d, J = 17.4 Hz, 1H), 2.19 (s, 9H), 1.67 
(s, 6H); 13C NMR (75 MHz, CDCl3) 6195.1 (e), 156.9 
(e), 156.9 (e), 151.9 (e), 138.4 (o), 130.5 (e), 129.8 (o), 
129.1 (o), 128.8 (o), 128.8 (o), 127.9 (o), 127.6 (e), 125.8 
(o), 120.8 (o), 113.5 (o), 110.9 (o), 98.5 (e), 92.6 (e), 89.9 
(e), 84.3 (e), 82.1 (e), 55.3 (e), 55.2 (o), 41.5 (e), 36.1 (e), 
30.9 (e), 27.9 (e); IR (CDCl3). 2913, 1721, 1697, 1496 
cm l; mass spec. (FAB) m/z calc'd for C34H31NO4Se: 
597.142, found 597.140; base peak 154, parent peak 597, 
554, 440, 396, 368, 307. 
X=O, R1 = OMe, R2 = Co2Ad, R3 = CH2COCH3. 
A solution of m-chloroperbenzoic acid (80%, 23.2 
mg, 0.134 mmol) in CH2C12 (0.2 mL) was added drop 
wise to a stirred solution of the phenyl selenide X=O, 
R1 = OMe, R2 = CO2Ad, R3 = SePh (59.0 mg, 0.1 
mmol), in CH2Cl2 (0.67 mL), under argon at -78 C. 
After the addition the reaction mixture was stirred at 
-78° C. for 45 min and then treated with 1-(trimethyl 
silyloxy)-1-methyl ethylene (200 mg, 1.54 mmole) fol 
lowed by (trimethylsilyl) trifluoromethane sulfonate 
(33.4 mg, 0.15 mmol). After 10 min at -78 C., the 
temperature was raised to 0 °C.; aq. Saturated NaHCO3 
(4.0 mL) was added, the mixture was diluted with 
CH2Cl2 (4.0 mL) and the phases were separated. The 
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organic phase was washed with aq. saturated NaHCO3 
(2.0 mL), dried (MgSO4), filtered and the solvent re 
moved in vacuo, to afford the crude product (79.3 mg). 
This material was chromatographed on a silica gel plate 
(1.0 mm thickness, 50:50 Et2O-pentante) to afford the 
1,4 diketone X=O, R1 =OMe, R2 = Co2Ad, 
R3=CH2COCH3 (25.0 mg, 51% yield). H NMR (300 
MHz, CDCl3) 87.22 (m, 1H), 6.82 (dd, J = 2.7, 8.9 Hz, 
1H), 6.70 (d, J =2.7 Hz, 1H), 6.11 (m, 1H), 5.75 (d, 
J=9.6 Hz 1H), 5.67 (d, J =9.6Hz 1H), 3.80 (s, 3H), 3.25 
(d, J = 24 Hz, 1H), 3.20 (d, J =24 Hz, 1H), 3.0 (m, 2H), 
2.18 (s, 9H), 1.86 (s, 3H), 1.65 (s, 6H); 13C NMR (75 
MHz, CDCl36202.6 (e), 157.4 (e), 153.4 (e), 133.3 (e), 
130.8 (e), 130.8 (e), 128.9 (o), 127.1 (o), 122.1 (o), 118.9 
(o), 112.8 (o), 112.0 (o), 99.9 (e), 93.8 (e), 89.9 (e), 84.2 
(e), 82.1 (e), 58.2 (e), 56.5 (o), 53.5 (e), 41.8 (e), 36.4 (e), 
32.3 (o) 32.2 (e), 30.1 (o); mass spec. (FAB) m/z calc'd 
for C31H31NO5: 497.220, found 497.222; base peak 368, 
parent peak 497, 499, 454, 410, 394, 346. 
X=O, R1 = OMe, R2 = CO2Ad, R3 = OH. 
The phenyl selenide X=O, R1 = OMe, R2 = CO2Ad, 
R3 = SePh. (65.5 mg, 0.11 mmol) was dissolved in ace 
tone (3.0 mL) and treated with excess (30-36 equiva 
lents) dennethyl dioxirane in acetone. Addition of water 
(0.2 mL) and warming of the reaction mixture to 40° C. 
resulted in complete consumption of the intermediate 
Selenoxide within 1 h. The solvent was removed in 
vacuo, the residue taken up in CH2Cl2 (8.0 mL) and the 
organic solution was washed with brine (2X4.0 mL). 
The organic pahse was separated, dried (MgSO4), fil 
tered and the solvent removed in vacuo. The crude 
product (86 mg) was purified by preparative plate chro 
matography (silica gel plate, 0.5 mm thickness, 50:50Et 
2O:pentane) to afford the title compound X=O, 
R=OMe, R2 = CO2Ad, R3 = OH. (34 mg, 68% yield) 
as an amorphous solid. Rf0.33 (50:50-etherpentane); H 
NMR (300 MHz, CDCl3) 87.45 (d, J =9.0 Hz, 1H), 6.99 
(d, J = 2.7 Hz, 1H), 6.91 (dd, J =2.7, 9.0Hz, 1H), 5.98 (d, 
J= 1.8 Hz, 1H), 5.81 (d, J =9.0 Hz, 1H), 5.68 (d, J = 1.8, 
9.0 Hz, 1H), 3.82 (s, 3H), 3.32 (s, 2H), 308 (m, 1H), 2.17 
(s, 3H), 2.13 (s, 6H), (s, 6H); 13C NMR (75 MHz, 
CDCl3) 8198.6 (e), 157.5 (e), 151.9 (e), 131.1 (e), 129.7 
(e), 127.7 (o), 126.5 (o), 121.3 (o), 15.1 (o), 111.8 (o), 
97.1 (e), 91.1 (e), 90.8 (e), 84.9 (e), 82.7 (e), 55.6 (o), 55.3 
(o), 41.4 (e), 36.0 (e), 30.9 (o), 30.1 (e); IR (CHCl3) 3750, 
1715, 1690 cm-l; mass spec. (CI) m/z calc'd for 
C28H28NOs; 458.197, found 458.195; base peak 135, 
parent peak 458, 460, 442,398, 326, 285. 
X=O, R =OMe, R2 = CO2Ad, R3 = OCOPh. 
A solution of lithium hexamethyldisilazane in THF 
(1.0M, 0.3 mL, 0.3 mmol) was added dropwise to a cold 
(-78 C.) solution of the carbamate R3 = H (110 mg, 
0.25 mmol) in THF (1.25 mL). The resulting yellow 
solution was stirred under argon for 35 min, warmed to 
0° C. and treated with solid benzoyl peroxide (121 mg, 
0.5 mmol). After 18 min at 0° C. aq. saturated NaHCO3 
(1.2 mL) was added and the mixture was extracted with 
Et2O (3X3.0 mL). The combined organic layers were 
washed with aq. saturated NaHCO3 (3 mL) then with 
brine (3 mL), dried (MgSO4), and filtered. Filtration 
and solvent removal in vacuo afforded the crude benzo 
ate (156 mg) as an orange amorphous solid. Flash chro 
matography on silica gel (7.5 g, 10:90 Et2O-pentane 
then 30:70-Et2O-pentane) afforded the title compound 
X=O, R1 =OMe, R2 = CO2Ad, R3 =OCOPh (77.0 mg, 
55% yield) as a white amorphous sold. Rf 0.36 
(2x20:80-etherpentane); H NMR (300 MHz, CDCl3) 












(m, 2H), 6.25 (n, 1H =9.0 Hz, 1H), 5.75 (dd, J = 1.8, 9.0 
Hz, 1H), 3.80 (s, 3H), 3.67 (d, J = 17.1 Hz, 3.58 (dd, 
J=17.1, 1.8 Hz, 1H), 2.20 (m, 9H), 1.65 (s, 6H); 13C 
NMR (75 MHz, CDCl3) 8195.3 (e), 157.1 (e), 152.4 (e), 
133.6 (o), 130.0 (o), 128.3 (o), 125.9 (o), 122.1 (o), 115.0 
(o), 112.6 (o), 95.9 (e), 92.9 (e), 89.0 (e), 84.6 (e), 81.9 (e), 
78.9 (e), 67.9 (e), 65.8 (e), 55.5 (o), 41.4 (e), 36.2 (e), 30.9 
(o), 29.7 (e), 25.7 (e), 16.4 (o), 15.2 (o); mass. spec. 
(FAB) m/z calc'd for C35H31NO6: 561.215, found 
561.215; base peak 154, parent peak 561, 517, 440, 384. 
X=O, R1 = OMe, R2 = CO2Me, R3 =SPh. 
To a cooled solution at -78° C. of ene-diyne R3 = H 
(23 mgs, 0.46 mmols) in THF (0.7 mls) was added 
KHMDS (0.5M in PhMe 0.110 mls 0.055 mmols) and 
stirred for two minutes. To this solution was added a 
solution of PhSSO2Ph (13.5 mgs, 0.055 mmols) in THF 
(mls). The mixture was stirred for a further 10 minutes 
at -78 C. and quenched with bicarbonate, poured 
onto ether and washed with bicarb, brine, dried over 
MgSO4 and evaporated under reduced pressure. Chro 
matography over silica (Hexane ether 8:2) gave the 
desired product X=O, R1=OMe, R2 = CO2Me, 
R3 =SPh. (22 mgs 78%). H NMR (300 MHz, CDCl3) 
87.35 (m 2H), 7.24 (s3H), 7.83 (dd 1H J =2.8, 8.8 Hz), 
6.39 (br-s 1H), 5.99 (br-s 1H), 5.71 (d 1H J = 10Hz), 
5.5.57 (d 1H J = 10Hz), 4.77 (td, 1H, J = 10.9, 4.4 Hz), 
3.65 (s3H), 3.53 (d 1H J = 17.4Hz), 3.23 (dd 1H J = 17.4, 
1.1Hz), 2.1 (m 2H), 1.8-0.66 (m 16H). 13C NMR (75 
MHz, CDCl3) 816.19, 21.03, 21.58, 21.99, 23.15, 26.35, 
31.43, 34.09, 34.14, 41.13, 41.18, 47.22, 54.78, 55.4.0, 
60.82, 77.18, 84.62, 90.04, 97.89, 101.76, 111.72, 112.14, 
113.96, 20.8, 126.02, 126.17, 129.43, 129.56, 130.22, 
136.58, 138.04, 157.25. IR (cm-1) (CHCl3). 3027 (w), 
3012 (w), 2960 (m), 2930 (m), 2872 (m), 1730 (m), 1705 
(s), 1611 (w), 1502 (s). HRMS C1+): 553.227512 
(C34H35NOsS requires 553.228681). 
X=O, R1=OMe, R2=H, R3=CH(OH)Ph. 
A 1.0M solution of lithium hexamethyldisilazide in 
tetrahydrofuran (561 u, 55.5 pmol, 1.00 equiv.) was 
added dropwise to a stirred solution of the bromoaniline 
X=O, R1=OMe, R2=H, R3=H (19.0 mg, 55.5 umol, 
1.00 equiv.) in anhydrous tetrahydrofuran (2ml) at 
-78°C. (CO2(s)/acetone). Chlorotrimethylsilane (7 ul, 
55.5 pmol, 1.00 equiv.) was added after 20 minutes and 
the clear colourless solution cooled to -95 C. (N20/- 
toluene). Distilled benzaldehyde (28 ul, 277 unol, 5.00 
equiv.) followed by a 1.7M solution of t-buytl lithium in 
pentane (66 ul, 110 umol, 2.00 equiv.) was added at 
-95 C. After stirring 15 minutes the cooling bath was 
removed and the clear brown solution allowed to warm 
to room temperture and quenched after 30 minutes with 
saturated aqueous sodium hydrogen carbonate (10 ml). 
Extraction with dichloromethane (1x10, 2x5 ml), 
drying of the organic extracts over anhydrous magne 
sium sulphate and evaporation gave a viscous brown oil 
(H NMR indicated a 1:1 mixture of starting material 
and aldol product, as a single diastereoisomer, with 
2,2-dimethyl-1-phenylpropan-1-ol byproduct). The 
crude reaction mixture was purified by preparative 
layer chromatography (silica, eluted 2:1 pentane:die 
thylether, Rf, starting material 0.40, aldol product 0.60, 
2,2-dimethyl-1-phenylpropan-1-ol 0.70) to give recov 
ered starting material (5.8 mg, 31%) and aldol product 
X=O, R1 = OMe, R2 = H, R3 = CH(OB)Ph. (7.0 mg, 
34%), as a viscous clear pale yellow oil. IR (C, HCl) 
3373 (w), 1732 (s). 1H NMR (CDCl3, 300MHz) 
87.25-7.15 (m, 3H), 7.00 (d, J = 2.7 Hz, 1H), 6.82 (d, 
J = 6.8 Hz, 1H), 5.74 (d, J = 2.7 Hz, 1H), 5.70 (dd, J = 1.6 
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and 9.5 Hz, 1H), 5.63 J =9.5 Hz, 1H), 5.04 (s, 1H), 4.65 
(d, J = 1.8 Hz, 1H), 3.48 (s, 3H), 3.33 (d, J = 17.2 Hz, 
1H), 2.61 (dd, J = 1.6 and 17.2Hz, 1H), -0.16 (s, 9H). 
13C NMR (CDCl3, 75MHz) 8201.98 (e), 152.08 (e), 
138.79 (e), 136.27 (e), 128.33 (e), 128.62 (o), 127.25 (o), 
125.69 (o), 124.08 (e), 121.49 (o), 117.37 (o), 114.79 (o), 
111.14 (e), 99.24 (e), 94.32 (e), 89.06 (e), 82.89 (e), 82.30 
(o), 63.51 (e), 55.61 (o), 54.23 (o), 26.26 (e), -0.33 (o). 
MS (Cl) base peak 179, M-I-H 0.6% base peak. HRMS 
C27H26NO3BrSi (M--)calculated 519.086533, found 
519.086507 (error 0.1 ppm). 
E-X-CHCN, R1 = OMe, R2 = CO2Ad, R3s H. 
A 2.5M solution of n-butyl lithium in hexanes (41 u, 
103 umol, 1.05 equiv.) was added dropwise to a stirred 
solution of diethyl cyanomethylphosphonate (17 u , 
108 umol, 1.10 equiv.) in anhydrous tetrahydrofuran 
(0.5 ml) at room temperature. After stirring for 40 min 
utes at room temperature the above clear colourless 
solution was added dropwise to a stirred solution of the 
bridghead ketone X=O, R1 = OMe, R2 = CO2Ad, 
R3 = H (43.2 mg, 98 umol, 1.00 equiv.) in tetrahydrofu 
ran (1.5 ml) at 0°C. The resulting clear orange solution 
was stirred at 0° C. for 20 minutes, eluted through a 
short column of silica with dichloromethane and evapo 
rated to give a viscous brown oil. Purification of the 
crude mixture by flash column chromatography (silica, 
eluted dichloromethane, Rf, starting material 0.45, olefi 
nated product 0.55) gave the olefinated product as a 
white amorphous solid (45.6mg, 85%). IR (CHCl3) 
2223 (w), 1694 (s); 1H NMR (300MHz, CDCl3) 
87.28–7.42 (m, br, 1H), 6.70–6.80 (m, 2H), 5.91 (s, br, 
1H), 5.78 (d, 1H, J =9.4Hz), 5.67 (d 1H, J=9.4Hz), 5.54 
(s, 1H), 4.22 (X of ABX, br, 1H), 3.79 (s, 3H), 3.56-3.38 
(AB of ABX, 2H), 2.17 (s, 3H), 2.10 (s, 6H) 1.64 (s, 6H); 
13C NMR (75MHz, CDCl3) 8160.49 (e), 156.96 (e), 
151.69 (e), 129.45 (e), 129.31 (e), 127.18 (o), 126.54 (o), 
121.73 (o), 115.32 (e), 112.43 (o), 111.26 (o), 100.20 (e), 
97.26 (o), 94.01 (e), 88.78 (e), 82.33 (e), 83.04 (e), 55.36 
(o), 49.40 (o), 41.46 (e), 40.27 (o), 35.98 (e), 30.82 (o), 
24.90 (e); MS (Cl) base peak m/z 135, (M--H)3% base 
peak, HRMS C30H28N2O3 (M+) calculated 464.209993, 
found 464,211623 (error 3.5ppm). 
X=O, R1 = OMe, R2 = CO2Ad, R3 = CH,OMe. A 
1.0M solution of lithium hexamethyldisilazide in tetra 
hydrofuran (481 pull, 481 umol, 1.05 equiv.) was added 
dropwise to a stirred solution of the bridghead ketone 
X=O, R1 = OMe, R2 = CO2Ad, R3 = H (202.2 mg, 458 
umol, 1.00 equiv.) in anhydrous tetrahydrofuran (4 ml) 
at -78 C. (CO2(s)/acetone). The clear pale yellow 
solution was stirred at -78 C. for 20 minutes and a 
solution of chloromethyl methylether (104 ul, 
1.37mmol, 3.00 equiv.) in tetrahydrofuran (1 ms) was 
added. After stirring 10 minutes at -78 C. the cooling 
bath was removed and the clear yellow solution al 
lowed to warm to room temperature. Quenching after 1 
hour at room temperature with saturated aqueous so 
dium hydrogen carbonate (10 ml), extraction with di 
chloromethane (1X 10, 2X5 ml), drying of the organic 
extracts with anhydrous magnesium sulphate and evap 
oration gave a viscous orange oil. The crude mixture 
was purified by flash column chromatography (silica, 
eluted dichloromethane, Rf, starting material 0.45, al 
kylated product 0.50) to give the alkylated product as a 
white amorphous solid (180.2 mg, 81%). IR (CHCl3) 
1734 (s), 1696 (s); H (300 MHz, CDCl3) 87.38 (s, wbr, 
1H), 6.82 (dd, br, 1H, J = 8.6 and 2.4Hz), 6.73 (d, 1H, 










(d, 1H, J =9.4Hz), 3.79 (s, 3H), 3.68 (d, 1H, J = 7.8Hz), 
24. 
3.32 (d, br, 1H, J = 7.8Hz), 3.16 (d, 1H, J = 17.5Hz), 3.05 
(s, 3H), 2.91 (dd, 1H, J = 17.5 and 1.8Hz), 2.14 (s, 3H), 
2.11 (s, 6H), 1.63 (s, 6H); 13C (75MHz, CDCl3) 8200.27 
(e), 157.22 (e), 152.18 (e, br), 132.57 (e, br), 130.64 (e), 
127.66 (o), 126.19 (o), 121.23 (o), 112.30 (o), 111.59 (o), 
98.26 (e), 91.15 (e, br), 90.82 (e), 83.43 (e), 81.53 (e), 
81.22 (e), 59.76 (o), 58.78 (e), 55.42 (o), 41.48 (e), 36.09 
(e), 30.87 (o), 25.21 (e), one CH resonance not detected; 
MS (CI) base peak m/z 135, (M--H) 25% base peak, 
HRMS (M--) C30H31NOscalculated 485.220223, found 
485.220290 (error 0.1 ppm). 
EXAMPLE 5 
An alternative route to the synthesis of compound 6 
of FIG. 1 is illustrated below. The advantage of this 
route is that one need start with 6-methoxyquinoline as 
a starting material, rather than a 3-hydroxy 6-methoxy 
quinoline. 6-methoxyquinoline is readily available and is 
a less expensive starting material. 
Preparation of Enol Ether 6 
A 1.OM solution of ethylmagnesium bromide in tetra 
hydrofuran (5 ml, 5 mmol, 1.00 equiv) was added drop 
wise to a stirred solution of 6-methoxyquinoline (796 
mg, 5 mmol, 1 equiv) and enediyne (951 mg, 5 mmol, 
1.00 equiv) in anhydrous tetrahydrofuran (40 ml) at 0 
C. The clear green solution was stirred for 30 min at 0° 
C. and a solution of l-adamantyl chloroformate (1.29 g, 
6 mmol, 1.2 equiv) in tetrahydrofuran (10 ml) added 
dropwise over 2 hrs (syringe pump). On completion of 
the addition, the cooling bath was removed and the 
mixture stirred 2 hrs at room temperature, quenched 
with water (30 ml), filtered, extracted with diethyl ether 
(1X50, 2X25 ml), the organic extracts dried over anhy 
drous magnesium sulfate and evaporated to give a vis 
cous brown oil. Purification of the crude mixture by 
flash column chromatography (silica, eluted 3:1, pen 
tane:diethyl ether, Rf, enediyne 0.70, coupled product 
0.25, 6-methoxyquinoline 0.20) gave the coupled prod 
uct as a yellow green foam (1.62 g, 61%). 
Meta-chloroperbenzoic acid (153.3 mg, 888 umol, 
3.00 equiv) was added to a rapidly stirred biphasic sys 
tem of coupled enediyne-quinoline (156.2 mg, 296 
umol, 1.00 equiv), 50% aqueous sodium hydrogen car 
bonate solution (5 ml) and dichloromethane (5 ml) at 
room temperature. After stirring for 2 hrs at room tem 
perature, the mixture was extracted with dichlorometh 
ane (3X 10 ml), the organic extracts dried over anhy 
drous magnesium sulfate and evaporated to give a vis 
cous yellow oil. Purification of the crude mixture by 
flash column chromatography (silica eluted 2:1, pen 
tane:diethyl ether, Rf, starting material 0.45, epoxide 
0.40) yielded the epoxide. 
Sodium borohydride (6.6 mg, 174 umol, 1.25 equiv) 
was added portionwise over 5 minto a stirred suspen 
sion of diphenyl diselenide (65.3 mg, 209 umol, 1.5 
equiv) in absolute ethanol (dried over 4. A sieves) at 
room temperature (water bath). After stirring 30 min, 
the clear yellow solution was added dropwise to a solu 
tion of the epoxide (75.8 mg, 139 umol, 1.00 equiv) in 
anhydrous tetrahydrofuran (1 ml) at room temperature. 
The resulting clear orange solution was stirred at room 
temperature until thin layer chromatography indicated 
complete consumption of the epoxide (10 hrs). Quench 
ing with water (20 ml), extraction with diethyl ether 
(1X30, 2X 15 ml), drying of the organic extracts over 
anhydrous magnesium sulfate and evaporation gave a 
viscous brown oil. Purification of the crude mixture by 
flash column chromatography (silica, eluted 2:1, pen 
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tane:diethyl ether, Rf, epoxide 0.40, selenated product 
0.30) gave the product as a viscous clear pale yellow oil 
(63.1 mg, 65%) 
A solution of tert-butyldimethylsilyl chloride (17.3 
mg, 115 umol, 1.20 equiv) in anhydrous dimethylform 
amide (1 ml, dried over 4A sieves) was added dropwise 
to a solution of the secondary alcohol (67.1 mg, 95.8 
umol, 1.00 equiv), imidazole (13.0 mg, 192 umol, 2.00 
equiv) in dimethylformamide (3 ml) at room tempera 
ture. The clear brown solution was stirred 9 hrs at room 
temperature, drawn-out into water (20 ml), extracted 
with diethyl ether (1X30, 2X 15 ml), the organic ex 
tracts dried over anhydrous magnesium sulfate and 
5 
10 
evaporated to give a yellow semi-solid. Purification of 15 
the crude mixture by flash column chromatography 
(silica, eluted 2:1, pentane:diethyl ether, Rf, secondary 
alcohol 0.40, silyl ether 0.55) gave the silylated product 
as a viscous clear yellow oil (70.0 mg, 90%). 
A solution of meta-perbenzoic acid (11.2 mg, 65.0 
umol, 1.20 equiv) in anhydrous dichloromethane (1 ml) 
was added dropwise to a stirred solution of the phenyl 
selenide (45.4 mg, 54.2 umol, 1.00 equiv) in dichloro 
methane (1 ml) at 0°C. The mixture was stirred 10 min 
at 0°C. in pyridine (13 ul, 163 umol, 3.00 equiv) added 
and the clear pale yellow solution heated to reflux. 
After 8 hr at reflux the mixture was cooled to room 
temperature and evaporated to give a brown oil. Purifi 
cation of the crude mixture by flash column chromatog 
raphy (silica, eluted 2% :1, pentane:diethyl ether, Rf, 
starting material 0.35, product 0.50) gave the silyl enol 
ether as a yellow foam. 
While the compositions and methods of this invention 
have been described in terms of preferred embodiments, 
it will be apparent to those of skill in the art that varia 
tions may be applied to the composition, methods, and 
in the steps or in the sequence of steps of the methods 
described herein without departing from the concept, 
spirit and scope of the invention. More specifically, it 
will be apparent that certain agents which are both 
chemically and physiologically related may be substi 
tuted for the agents described herein while the same or 
similar results would be achieved. All such similar sub 
stitutes and modifications apparent to those skilled in 
the art are deemed to be within the spirit, scope and 
concept of the invention as defined by the appended 
claims. All claimed matter and methods can be made 
and executed without undue experimentation. 
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What is claimed is: 
1. A compound of the formula; 
wherein R1 is H, COOAd, COOCH2CH2Cl, COOCH3, 
CH(CH3)2, cholesterol or menthyl; R2 is H or OCH3; 
R3 is SePh, CH2COCH3, OH, OCOPh, -SPh, 
CH(OH) Ph, H or CH2OMe, R4 is CHCH, CH2, O or 
CHCO2Me except that R2 or R3 is not H when R1 is 
-COOCH3 and pharmaceutically acceptable salts 
thereof. 
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